HRP20120895T1 - Imidazokinolini sa imuno-modulacijskim svojstvima - Google Patents
Imidazokinolini sa imuno-modulacijskim svojstvima Download PDFInfo
- Publication number
- HRP20120895T1 HRP20120895T1 HRP20120895AT HRP20120895T HRP20120895T1 HR P20120895 T1 HRP20120895 T1 HR P20120895T1 HR P20120895A T HRP20120895A T HR P20120895AT HR P20120895 T HRP20120895 T HR P20120895T HR P20120895 T1 HRP20120895 T1 HR P20120895T1
- Authority
- HR
- Croatia
- Prior art keywords
- methyl
- amino
- quinolin
- imidazo
- propyl
- Prior art date
Links
- RHKWIGHJGOEUSM-UHFFFAOYSA-N 3h-imidazo[4,5-h]quinoline Chemical class C1=CN=C2C(N=CN3)=C3C=CC2=C1 RHKWIGHJGOEUSM-UHFFFAOYSA-N 0.000 title 1
- 230000002519 immonomodulatory effect Effects 0.000 title 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 42
- 150000001875 compounds Chemical class 0.000 claims 35
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 24
- -1 cyano, hydroxyl Chemical group 0.000 claims 22
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 20
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 claims 18
- 150000003839 salts Chemical class 0.000 claims 14
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 claims 10
- 229910052736 halogen Inorganic materials 0.000 claims 7
- 150000002367 halogens Chemical class 0.000 claims 7
- 229910052739 hydrogen Inorganic materials 0.000 claims 7
- 239000001257 hydrogen Substances 0.000 claims 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 7
- 229910052760 oxygen Inorganic materials 0.000 claims 7
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 6
- 125000000623 heterocyclic group Chemical group 0.000 claims 6
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 5
- 125000004093 cyano group Chemical group *C#N 0.000 claims 5
- 229910052757 nitrogen Inorganic materials 0.000 claims 5
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims 5
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 5
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 4
- 150000002016 disaccharides Chemical class 0.000 claims 4
- OAFYFGINDSGHDR-UHFFFAOYSA-N methyl 2-[4-[[3-(4-amino-2-butylimidazo[4,5-c]quinolin-1-yl)propyl-[2-(dimethylamino)acetyl]amino]methyl]phenyl]acetate Chemical compound CCCCC1=NC2=C(N)N=C3C=CC=CC3=C2N1CCCN(C(=O)CN(C)C)CC1=CC=C(CC(=O)OC)C=C1 OAFYFGINDSGHDR-UHFFFAOYSA-N 0.000 claims 4
- 125000001424 substituent group Chemical group 0.000 claims 4
- 125000002947 alkylene group Chemical group 0.000 claims 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 3
- 229910052717 sulfur Inorganic materials 0.000 claims 3
- 125000006595 (C1-C3) alkylsulfinyl group Chemical group 0.000 claims 2
- 125000006594 (C1-C3) alkylsulfony group Chemical group 0.000 claims 2
- 125000004455 (C1-C3) alkylthio group Chemical group 0.000 claims 2
- 125000006677 (C1-C3) haloalkoxy group Chemical group 0.000 claims 2
- 125000006699 (C1-C3) hydroxyalkyl group Chemical group 0.000 claims 2
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims 2
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical group C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- CARVEAKPQSZLKP-UHFFFAOYSA-N methyl 2-[3-[[3-(4-amino-2-butylimidazo[4,5-c]quinolin-1-yl)propyl-(1-methylpiperidin-4-yl)amino]methyl]phenyl]acetate Chemical compound CCCCC1=NC2=C(N)N=C3C=CC=CC3=C2N1CCCN(C1CCN(C)CC1)CC1=CC=CC(CC(=O)OC)=C1 CARVEAKPQSZLKP-UHFFFAOYSA-N 0.000 claims 2
- UIVIPXGEVSLKEY-UHFFFAOYSA-N methyl 2-[3-[[3-(4-amino-2-butylimidazo[4,5-c]quinolin-1-yl)propyl-(2-morpholin-4-ylacetyl)amino]methyl]phenyl]acetate Chemical compound CCCCC1=NC2=C(N)N=C3C=CC=CC3=C2N1CCCN(C(=O)CN1CCOCC1)CC1=CC=CC(CC(=O)OC)=C1 UIVIPXGEVSLKEY-UHFFFAOYSA-N 0.000 claims 2
- HCCJVWXUQYDTCH-UHFFFAOYSA-N methyl 2-[3-[[3-(4-amino-2-butylimidazo[4,5-c]quinolin-1-yl)propyl-(2-piperidin-1-ylacetyl)amino]methyl]phenyl]acetate Chemical compound CCCCC1=NC2=C(N)N=C3C=CC=CC3=C2N1CCCN(C(=O)CN1CCCCC1)CC1=CC=CC(CC(=O)OC)=C1 HCCJVWXUQYDTCH-UHFFFAOYSA-N 0.000 claims 2
- CQWGSSPDVHWUFF-UHFFFAOYSA-N methyl 2-[3-[[3-(4-amino-2-butylimidazo[4,5-c]quinolin-1-yl)propyl-(2-pyrrolidin-1-ylacetyl)amino]methyl]phenyl]acetate Chemical compound CCCCC1=NC2=C(N)N=C3C=CC=CC3=C2N1CCCN(C(=O)CN1CCCC1)CC1=CC=CC(CC(=O)OC)=C1 CQWGSSPDVHWUFF-UHFFFAOYSA-N 0.000 claims 2
- JXRWVFKUUVEFAW-UHFFFAOYSA-N methyl 2-[3-[[3-(4-amino-2-butylimidazo[4,5-c]quinolin-1-yl)propyl-(3-morpholin-4-ylpropyl)amino]methyl]phenyl]acetate Chemical compound CCCCC1=NC2=C(N)N=C3C=CC=CC3=C2N1CCCN(CC=1C=C(CC(=O)OC)C=CC=1)CCCN1CCOCC1 JXRWVFKUUVEFAW-UHFFFAOYSA-N 0.000 claims 2
- XDCGQPFRLPMZKQ-UHFFFAOYSA-N methyl 2-[3-[[3-(4-amino-2-butylimidazo[4,5-c]quinolin-1-yl)propyl-[2-(1,4-oxazepan-4-yl)acetyl]amino]methyl]phenyl]acetate Chemical compound CCCCC1=NC2=C(N)N=C3C=CC=CC3=C2N1CCCN(C(=O)CN1CCOCCC1)CC1=CC=CC(CC(=O)OC)=C1 XDCGQPFRLPMZKQ-UHFFFAOYSA-N 0.000 claims 2
- VIUKMRIXTOCAIL-UHFFFAOYSA-N methyl 2-[3-[[3-(4-amino-2-butylimidazo[4,5-c]quinolin-1-yl)propyl-[2-(3-hydroxyazetidin-1-yl)acetyl]amino]methyl]phenyl]acetate Chemical compound CCCCC1=NC2=C(N)N=C3C=CC=CC3=C2N1CCCN(C(=O)CN1CC(O)C1)CC1=CC=CC(CC(=O)OC)=C1 VIUKMRIXTOCAIL-UHFFFAOYSA-N 0.000 claims 2
- YWFAPMNKHRMMFS-UHFFFAOYSA-N methyl 2-[3-[[3-(4-amino-2-butylimidazo[4,5-c]quinolin-1-yl)propyl-[2-(3-hydroxypyrrolidin-1-yl)acetyl]amino]methyl]phenyl]acetate Chemical compound CCCCC1=NC2=C(N)N=C3C=CC=CC3=C2N1CCCN(C(=O)CN1CC(O)CC1)CC1=CC=CC(CC(=O)OC)=C1 YWFAPMNKHRMMFS-UHFFFAOYSA-N 0.000 claims 2
- SVFXDRXNTFGFAD-UHFFFAOYSA-N methyl 2-[3-[[3-(4-amino-2-butylimidazo[4,5-c]quinolin-1-yl)propyl-[2-(4-hydroxypiperidin-1-yl)acetyl]amino]methyl]phenyl]acetate Chemical compound CCCCC1=NC2=C(N)N=C3C=CC=CC3=C2N1CCCN(C(=O)CN1CCC(O)CC1)CC1=CC=CC(CC(=O)OC)=C1 SVFXDRXNTFGFAD-UHFFFAOYSA-N 0.000 claims 2
- LYPNDXHMUCFPAF-UHFFFAOYSA-N methyl 2-[3-[[3-(4-amino-2-butylimidazo[4,5-c]quinolin-1-yl)propyl-[2-(4-methoxypiperidin-1-yl)acetyl]amino]methyl]phenyl]acetate Chemical compound CCCCC1=NC2=C(N)N=C3C=CC=CC3=C2N1CCCN(C(=O)CN1CCC(CC1)OC)CC1=CC=CC(CC(=O)OC)=C1 LYPNDXHMUCFPAF-UHFFFAOYSA-N 0.000 claims 2
- ZJCGWXDMMYLJHZ-UHFFFAOYSA-N methyl 2-[3-[[3-(4-amino-2-butylimidazo[4,5-c]quinolin-1-yl)propyl-[2-(4-methyl-1,4-diazepan-1-yl)acetyl]amino]methyl]phenyl]acetate Chemical compound CCCCC1=NC2=C(N)N=C3C=CC=CC3=C2N1CCCN(C(=O)CN1CCN(C)CCC1)CC1=CC=CC(CC(=O)OC)=C1 ZJCGWXDMMYLJHZ-UHFFFAOYSA-N 0.000 claims 2
- XLYSJIJBMCZOFD-UHFFFAOYSA-N methyl 2-[3-[[3-(4-amino-2-butylimidazo[4,5-c]quinolin-1-yl)propyl-[2-(4-methylpiperazin-1-yl)acetyl]amino]methyl]phenyl]acetate Chemical compound CCCCC1=NC2=C(N)N=C3C=CC=CC3=C2N1CCCN(C(=O)CN1CCN(C)CC1)CC1=CC=CC(CC(=O)OC)=C1 XLYSJIJBMCZOFD-UHFFFAOYSA-N 0.000 claims 2
- KYPGMBKNBVAKPS-UHFFFAOYSA-N methyl 2-[3-[[3-(4-amino-2-butylimidazo[4,5-c]quinolin-1-yl)propyl-[2-(4-methylsulfonyl-1,4-diazepan-1-yl)acetyl]amino]methyl]phenyl]acetate Chemical compound CCCCC1=NC2=C(N)N=C3C=CC=CC3=C2N1CCCN(C(=O)CN1CCN(CCC1)S(C)(=O)=O)CC1=CC=CC(CC(=O)OC)=C1 KYPGMBKNBVAKPS-UHFFFAOYSA-N 0.000 claims 2
- ASIRWIVQGZUAHB-UHFFFAOYSA-N methyl 2-[3-[[3-(4-amino-2-butylimidazo[4,5-c]quinolin-1-yl)propyl-[2-(azepan-1-yl)acetyl]amino]methyl]phenyl]acetate Chemical compound CCCCC1=NC2=C(N)N=C3C=CC=CC3=C2N1CCCN(C(=O)CN1CCCCCC1)CC1=CC=CC(CC(=O)OC)=C1 ASIRWIVQGZUAHB-UHFFFAOYSA-N 0.000 claims 2
- WJZDYZUKXBCLFY-UHFFFAOYSA-N methyl 2-[3-[[3-(4-amino-2-butylimidazo[4,5-c]quinolin-1-yl)propyl-[2-(azetidin-1-yl)acetyl]amino]methyl]phenyl]acetate Chemical compound CCCCC1=NC2=C(N)N=C3C=CC=CC3=C2N1CCCN(C(=O)CN1CCC1)CC1=CC=CC(CC(=O)OC)=C1 WJZDYZUKXBCLFY-UHFFFAOYSA-N 0.000 claims 2
- REYOPNVVVPNASZ-PLQXJYEYSA-N methyl 2-[3-[[3-(4-amino-2-butylimidazo[4,5-c]quinolin-1-yl)propyl-[2-[(2r,6s)-2,6-dimethylmorpholin-4-yl]acetyl]amino]methyl]phenyl]acetate Chemical compound CCCCC1=NC2=C(N)N=C3C=CC=CC3=C2N1CCCN(C(=O)CN1C[C@@H](C)O[C@@H](C)C1)CC1=CC=CC(CC(=O)OC)=C1 REYOPNVVVPNASZ-PLQXJYEYSA-N 0.000 claims 2
- YWFAPMNKHRMMFS-RUZDIDTESA-N methyl 2-[3-[[3-(4-amino-2-butylimidazo[4,5-c]quinolin-1-yl)propyl-[2-[(3r)-3-hydroxypyrrolidin-1-yl]acetyl]amino]methyl]phenyl]acetate Chemical compound CCCCC1=NC2=C(N)N=C3C=CC=CC3=C2N1CCCN(C(=O)CN1C[C@H](O)CC1)CC1=CC=CC(CC(=O)OC)=C1 YWFAPMNKHRMMFS-RUZDIDTESA-N 0.000 claims 2
- IWDSQAIXLBTIEE-UHFFFAOYSA-N methyl 2-[3-[[3-(4-amino-2-butylimidazo[4,5-c]quinolin-1-yl)propyl-[2-[2-methoxyethyl(methyl)amino]acetyl]amino]methyl]phenyl]acetate Chemical compound CCCCC1=NC2=C(N)N=C3C=CC=CC3=C2N1CCCN(C(=O)CN(C)CCOC)CC1=CC=CC(CC(=O)OC)=C1 IWDSQAIXLBTIEE-UHFFFAOYSA-N 0.000 claims 2
- AJXWMDOGABJQCB-UHFFFAOYSA-N methyl 2-[3-[[3-(4-amino-2-butylimidazo[4,5-c]quinolin-1-yl)propyl-[2-[4-(ethylcarbamoyl)-1,4-diazepan-1-yl]acetyl]amino]methyl]phenyl]acetate Chemical compound CCCCC1=NC2=C(N)N=C3C=CC=CC3=C2N1CCCN(C(=O)CN1CCN(CCC1)C(=O)NCC)CC1=CC=CC(CC(=O)OC)=C1 AJXWMDOGABJQCB-UHFFFAOYSA-N 0.000 claims 2
- ICEKWPYJHOUFIF-UHFFFAOYSA-N methyl 2-[3-[[3-(4-amino-2-butylimidazo[4,5-c]quinolin-1-yl)propyl-[2-[bis(2-hydroxyethyl)amino]acetyl]amino]methyl]phenyl]acetate Chemical compound CCCCC1=NC2=C(N)N=C3C=CC=CC3=C2N1CCCN(C(=O)CN(CCO)CCO)CC1=CC=CC(CC(=O)OC)=C1 ICEKWPYJHOUFIF-UHFFFAOYSA-N 0.000 claims 2
- KPQFVWZPJIIRQQ-UHFFFAOYSA-N methyl 2-[3-[[3-(4-amino-2-butylimidazo[4,5-c]quinolin-1-yl)propyl-[2-[butyl(methyl)amino]acetyl]amino]methyl]phenyl]acetate Chemical compound CCCCC1=NC2=C(N)N=C3C=CC=CC3=C2N1CCCN(C(=O)CN(C)CCCC)CC1=CC=CC(CC(=O)OC)=C1 KPQFVWZPJIIRQQ-UHFFFAOYSA-N 0.000 claims 2
- KZPHNBDDMMHSPN-UHFFFAOYSA-N methyl 2-[3-[[3-(4-amino-2-butylimidazo[4,5-c]quinolin-1-yl)propyl-[2-[methyl(oxan-4-yl)amino]acetyl]amino]methyl]phenyl]acetate Chemical compound CCCCC1=NC2=C(N)N=C3C=CC=CC3=C2N1CCCN(C(=O)CN(C)C1CCOCC1)CC1=CC=CC(CC(=O)OC)=C1 KZPHNBDDMMHSPN-UHFFFAOYSA-N 0.000 claims 2
- VEDCUJSSWBHNNY-UHFFFAOYSA-N methyl 2-[3-[[3-(4-amino-2-butylimidazo[4,5-c]quinolin-1-yl)propyl-[3-(4-methylpiperazin-1-yl)propyl]amino]methyl]phenyl]acetate Chemical compound CCCCC1=NC2=C(N)N=C3C=CC=CC3=C2N1CCCN(CC=1C=C(CC(=O)OC)C=CC=1)CCCN1CCN(C)CC1 VEDCUJSSWBHNNY-UHFFFAOYSA-N 0.000 claims 2
- LZHLVRRBAUBVRX-UHFFFAOYSA-N methyl 2-[3-[[3-(4-amino-2-butylimidazo[4,5-c]quinolin-1-yl)propyl-[3-(dimethylamino)propyl]amino]methyl]phenyl]acetate Chemical compound CCCCC1=NC2=C(N)N=C3C=CC=CC3=C2N1CCCN(CCCN(C)C)CC1=CC=CC(CC(=O)OC)=C1 LZHLVRRBAUBVRX-UHFFFAOYSA-N 0.000 claims 2
- DPFWTVXXNGIJTB-UHFFFAOYSA-N methyl 2-[3-[[3-(4-amino-2-butylimidazo[4,5-c]quinolin-1-yl)propyl-[3-[ethyl(methyl)amino]propyl]amino]methyl]phenyl]acetate Chemical compound CCCCC1=NC2=C(N)N=C3C=CC=CC3=C2N1CCCN(CCCN(C)CC)CC1=CC=CC(CC(=O)OC)=C1 DPFWTVXXNGIJTB-UHFFFAOYSA-N 0.000 claims 2
- VIMMXFYSJXUVJE-UHFFFAOYSA-N methyl 2-[3-[[3-(4-amino-2-butylimidazo[4,5-c]quinolin-1-yl)propylamino]methyl]phenyl]acetate Chemical compound CCCCC1=NC2=C(N)N=C3C=CC=CC3=C2N1CCCNCC1=CC=CC(CC(=O)OC)=C1 VIMMXFYSJXUVJE-UHFFFAOYSA-N 0.000 claims 2
- CKMOTWKYHIGXFY-UHFFFAOYSA-N methyl 2-[3-[[3-[4-amino-2-(2-methoxyethyl)imidazo[4,5-c]quinolin-1-yl]propyl-(2-piperidin-1-ylacetyl)amino]methyl]phenyl]acetate Chemical compound COCCC1=NC2=C(N)N=C3C=CC=CC3=C2N1CCCN(C(=O)CN1CCCCC1)CC1=CC=CC(CC(=O)OC)=C1 CKMOTWKYHIGXFY-UHFFFAOYSA-N 0.000 claims 2
- LKRPXKGFSKFBQC-UHFFFAOYSA-N methyl 2-[3-[[3-[4-amino-2-(2-methoxyethyl)imidazo[4,5-c]quinolin-1-yl]propyl-[2-(4-methylpiperazin-1-yl)acetyl]amino]methyl]phenyl]acetate Chemical compound COCCC1=NC2=C(N)N=C3C=CC=CC3=C2N1CCCN(C(=O)CN1CCN(C)CC1)CC1=CC=CC(CC(=O)OC)=C1 LKRPXKGFSKFBQC-UHFFFAOYSA-N 0.000 claims 2
- PDZQKBRQBIPYRX-UHFFFAOYSA-N methyl 2-[3-[[3-[4-amino-2-(2-methoxyethyl)imidazo[4,5-c]quinolin-1-yl]propyl-[2-[4-(2-methoxyethyl)piperazin-1-yl]acetyl]amino]methyl]phenyl]acetate Chemical compound C1CN(CCOC)CCN1CC(=O)N(CC=1C=C(CC(=O)OC)C=CC=1)CCCN1C2=C3C=CC=CC3=NC(N)=C2N=C1CCOC PDZQKBRQBIPYRX-UHFFFAOYSA-N 0.000 claims 2
- LEISSPDNWSLBRZ-UHFFFAOYSA-N methyl 2-[3-[[3-[4-amino-2-(ethoxymethyl)imidazo[4,5-c]quinolin-1-yl]propyl-[2-(dimethylamino)acetyl]amino]methyl]phenyl]acetate Chemical compound CCOCC1=NC2=C(N)N=C3C=CC=CC3=C2N1CCCN(C(=O)CN(C)C)CC1=CC=CC(CC(=O)OC)=C1 LEISSPDNWSLBRZ-UHFFFAOYSA-N 0.000 claims 2
- ROHZFOMXMXPLTC-UHFFFAOYSA-N methyl 2-[3-[[[2-(4-acetylpiperazin-1-yl)acetyl]-[3-(4-amino-2-butylimidazo[4,5-c]quinolin-1-yl)propyl]amino]methyl]phenyl]acetate Chemical compound CCCCC1=NC2=C(N)N=C3C=CC=CC3=C2N1CCCN(C(=O)CN1CCN(CC1)C(C)=O)CC1=CC=CC(CC(=O)OC)=C1 ROHZFOMXMXPLTC-UHFFFAOYSA-N 0.000 claims 2
- GOXIVZHBIPWDCC-UHFFFAOYSA-N methyl 2-[4-[[3-(4-amino-2-butylimidazo[4,5-c]quinolin-1-yl)propyl-(1-methylpiperidin-4-yl)amino]methyl]phenyl]acetate Chemical compound CCCCC1=NC2=C(N)N=C3C=CC=CC3=C2N1CCCN(C1CCN(C)CC1)CC1=CC=C(CC(=O)OC)C=C1 GOXIVZHBIPWDCC-UHFFFAOYSA-N 0.000 claims 2
- JESLMFCDDXPVAC-UHFFFAOYSA-N methyl 2-[4-[[3-(4-amino-2-butylimidazo[4,5-c]quinolin-1-yl)propyl-(2-methylsulfonylacetyl)amino]methyl]phenyl]acetate Chemical compound CCCCC1=NC2=C(N)N=C3C=CC=CC3=C2N1CCCN(C(=O)CS(C)(=O)=O)CC1=CC=C(CC(=O)OC)C=C1 JESLMFCDDXPVAC-UHFFFAOYSA-N 0.000 claims 2
- DWFOPGQSOBAJKR-UHFFFAOYSA-N methyl 2-[4-[[3-(4-amino-2-butylimidazo[4,5-c]quinolin-1-yl)propyl-(2-piperidin-1-ylacetyl)amino]methyl]phenyl]acetate Chemical compound CCCCC1=NC2=C(N)N=C3C=CC=CC3=C2N1CCCN(C(=O)CN1CCCCC1)CC1=CC=C(CC(=O)OC)C=C1 DWFOPGQSOBAJKR-UHFFFAOYSA-N 0.000 claims 2
- BJHUVAVJIWESCC-UHFFFAOYSA-N methyl 2-[4-[[3-(4-amino-2-butylimidazo[4,5-c]quinolin-1-yl)propyl-[2-(4-methylpiperazin-1-yl)acetyl]amino]methyl]phenyl]acetate Chemical compound CCCCC1=NC2=C(N)N=C3C=CC=CC3=C2N1CCCN(C(=O)CN1CCN(C)CC1)CC1=CC=C(CC(=O)OC)C=C1 BJHUVAVJIWESCC-UHFFFAOYSA-N 0.000 claims 2
- HJIFSDUTJZSBIF-UHFFFAOYSA-N methyl 2-[4-[[3-(4-amino-2-butylimidazo[4,5-c]quinolin-1-yl)propyl-[2-(4-methylsulfonyl-1,4-diazepan-1-yl)acetyl]amino]methyl]phenyl]acetate Chemical compound CCCCC1=NC2=C(N)N=C3C=CC=CC3=C2N1CCCN(C(=O)CN1CCN(CCC1)S(C)(=O)=O)CC1=CC=C(CC(=O)OC)C=C1 HJIFSDUTJZSBIF-UHFFFAOYSA-N 0.000 claims 2
- JUEZMCCALJINEA-UHFFFAOYSA-N methyl 2-[4-[[3-(4-amino-2-butylimidazo[4,5-c]quinolin-1-yl)propyl-[2-(4-pyrimidin-2-ylpiperazin-1-yl)acetyl]amino]methyl]phenyl]acetate Chemical compound CCCCC1=NC2=C(N)N=C3C=CC=CC3=C2N1CCCN(C(=O)CN1CCN(CC1)C=1N=CC=CN=1)CC1=CC=C(CC(=O)OC)C=C1 JUEZMCCALJINEA-UHFFFAOYSA-N 0.000 claims 2
- WPISGLOWKAPJDW-RUZDIDTESA-N methyl 2-[4-[[3-(4-amino-2-butylimidazo[4,5-c]quinolin-1-yl)propyl-[2-[(3r)-3-hydroxypyrrolidin-1-yl]acetyl]amino]methyl]phenyl]acetate Chemical compound CCCCC1=NC2=C(N)N=C3C=CC=CC3=C2N1CCCN(C(=O)CN1C[C@H](O)CC1)CC1=CC=C(CC(=O)OC)C=C1 WPISGLOWKAPJDW-RUZDIDTESA-N 0.000 claims 2
- XXMCSDCNXCWIMX-UHFFFAOYSA-N methyl 2-[4-[[3-(4-amino-2-butylimidazo[4,5-c]quinolin-1-yl)propyl-[2-[2-methoxyethyl(methyl)amino]acetyl]amino]methyl]phenyl]acetate Chemical compound CCCCC1=NC2=C(N)N=C3C=CC=CC3=C2N1CCCN(C(=O)CN(C)CCOC)CC1=CC=C(CC(=O)OC)C=C1 XXMCSDCNXCWIMX-UHFFFAOYSA-N 0.000 claims 2
- IFMMVHLTGHKTQC-UHFFFAOYSA-N methyl 2-[4-[[3-(4-amino-2-butylimidazo[4,5-c]quinolin-1-yl)propyl-[2-[4-[(2-methylpropan-2-yl)oxycarbonylamino]piperidin-1-yl]acetyl]amino]methyl]phenyl]acetate Chemical compound CCCCC1=NC2=C(N)N=C3C=CC=CC3=C2N1CCCN(C(=O)CN1CCC(CC1)NC(=O)OC(C)(C)C)CC1=CC=C(CC(=O)OC)C=C1 IFMMVHLTGHKTQC-UHFFFAOYSA-N 0.000 claims 2
- XIQQEASYCSFTBJ-UHFFFAOYSA-N methyl 2-[4-[[3-(4-amino-2-butylimidazo[4,5-c]quinolin-1-yl)propylamino]methyl]phenyl]acetate Chemical compound CCCCC1=NC2=C(N)N=C3C=CC=CC3=C2N1CCCNCC1=CC=C(CC(=O)OC)C=C1 XIQQEASYCSFTBJ-UHFFFAOYSA-N 0.000 claims 2
- VXXSVMYETJWPJF-UHFFFAOYSA-N methyl 2-[4-[[3-[4-amino-2-(2-methoxyethyl)imidazo[4,5-c]quinolin-1-yl]propyl-(2-piperidin-1-ylacetyl)amino]methyl]phenyl]acetate Chemical compound COCCC1=NC2=C(N)N=C3C=CC=CC3=C2N1CCCN(C(=O)CN1CCCCC1)CC1=CC=C(CC(=O)OC)C=C1 VXXSVMYETJWPJF-UHFFFAOYSA-N 0.000 claims 2
- WCZWCGDYHVIAEI-UHFFFAOYSA-N methyl 2-[4-[[3-[4-amino-2-(2-methoxyethyl)imidazo[4,5-c]quinolin-1-yl]propyl-(3-morpholin-4-ylpropyl)amino]methyl]phenyl]acetate Chemical compound COCCC1=NC2=C(N)N=C3C=CC=CC3=C2N1CCCN(CC=1C=CC(CC(=O)OC)=CC=1)CCCN1CCOCC1 WCZWCGDYHVIAEI-UHFFFAOYSA-N 0.000 claims 2
- QSNHNVFMEXXRHY-UHFFFAOYSA-N methyl 2-[4-[[3-[4-amino-2-(2-methoxyethyl)imidazo[4,5-c]quinolin-1-yl]propyl-(3-piperidin-1-ylpropanoyl)amino]methyl]phenyl]acetate Chemical compound COCCC1=NC2=C(N)N=C3C=CC=CC3=C2N1CCCN(C(=O)CCN1CCCCC1)CC1=CC=C(CC(=O)OC)C=C1 QSNHNVFMEXXRHY-UHFFFAOYSA-N 0.000 claims 2
- JAFVJOPWLXIGNO-UHFFFAOYSA-N methyl 2-[4-[[3-[4-amino-2-(2-methoxyethyl)imidazo[4,5-c]quinolin-1-yl]propyl-[2-(4-methylpiperazin-1-yl)acetyl]amino]methyl]phenyl]acetate Chemical compound COCCC1=NC2=C(N)N=C3C=CC=CC3=C2N1CCCN(C(=O)CN1CCN(C)CC1)CC1=CC=C(CC(=O)OC)C=C1 JAFVJOPWLXIGNO-UHFFFAOYSA-N 0.000 claims 2
- RRDDJWNSVSLZSN-UHFFFAOYSA-N methyl 2-[4-[[3-[4-amino-2-(2-methoxyethyl)imidazo[4,5-c]quinolin-1-yl]propyl-[2-(dimethylamino)acetyl]amino]methyl]phenyl]acetate Chemical compound COCCC1=NC2=C(N)N=C3C=CC=CC3=C2N1CCCN(C(=O)CN(C)C)CC1=CC=C(CC(=O)OC)C=C1 RRDDJWNSVSLZSN-UHFFFAOYSA-N 0.000 claims 2
- XUCFLUDSZIBEAB-AREMUKBSSA-N methyl 2-[4-[[3-[4-amino-2-(2-methoxyethyl)imidazo[4,5-c]quinolin-1-yl]propyl-[2-[(2r)-2-(methoxymethyl)pyrrolidin-1-yl]acetyl]amino]methyl]phenyl]acetate Chemical compound COCCC1=NC2=C(N)N=C3C=CC=CC3=C2N1CCCN(C(=O)CN1[C@H](CCC1)COC)CC1=CC=C(CC(=O)OC)C=C1 XUCFLUDSZIBEAB-AREMUKBSSA-N 0.000 claims 2
- XUCFLUDSZIBEAB-SANMLTNESA-N methyl 2-[4-[[3-[4-amino-2-(2-methoxyethyl)imidazo[4,5-c]quinolin-1-yl]propyl-[2-[(2s)-2-(methoxymethyl)pyrrolidin-1-yl]acetyl]amino]methyl]phenyl]acetate Chemical compound COCCC1=NC2=C(N)N=C3C=CC=CC3=C2N1CCCN(C(=O)CN1[C@@H](CCC1)COC)CC1=CC=C(CC(=O)OC)C=C1 XUCFLUDSZIBEAB-SANMLTNESA-N 0.000 claims 2
- ILBUXURHSVQYFN-UHFFFAOYSA-N methyl 2-[4-[[3-[4-amino-2-(2-methoxyethyl)imidazo[4,5-c]quinolin-1-yl]propyl-[2-[2-hydroxyethyl(methyl)amino]acetyl]amino]methyl]phenyl]acetate Chemical compound COCCC1=NC2=C(N)N=C3C=CC=CC3=C2N1CCCN(C(=O)CN(C)CCO)CC1=CC=C(CC(=O)OC)C=C1 ILBUXURHSVQYFN-UHFFFAOYSA-N 0.000 claims 2
- LTFLHHBTALZTMI-UHFFFAOYSA-N methyl 2-[4-[[3-[4-amino-2-(2-methoxyethyl)imidazo[4,5-c]quinolin-1-yl]propyl-[2-[2-methoxyethyl(methyl)amino]acetyl]amino]methyl]phenyl]acetate Chemical compound COCCC1=NC2=C(N)N=C3C=CC=CC3=C2N1CCCN(C(=O)CN(C)CCOC)CC1=CC=C(CC(=O)OC)C=C1 LTFLHHBTALZTMI-UHFFFAOYSA-N 0.000 claims 2
- PVLZGSGXJDZIPR-UHFFFAOYSA-N methyl 2-[4-[[3-[4-amino-2-(2-methoxyethyl)imidazo[4,5-c]quinolin-1-yl]propyl-[2-[4-(2-methoxyethyl)piperazin-1-yl]acetyl]amino]methyl]phenyl]acetate Chemical compound C1CN(CCOC)CCN1CC(=O)N(CC=1C=CC(CC(=O)OC)=CC=1)CCCN1C2=C3C=CC=CC3=NC(N)=C2N=C1CCOC PVLZGSGXJDZIPR-UHFFFAOYSA-N 0.000 claims 2
- BPZZWUMXCXBSHE-UHFFFAOYSA-N methyl 2-[4-[[[2-(4-acetylpiperazin-1-yl)acetyl]-[3-(4-amino-2-butylimidazo[4,5-c]quinolin-1-yl)propyl]amino]methyl]phenyl]acetate Chemical compound CCCCC1=NC2=C(N)N=C3C=CC=CC3=C2N1CCCN(C(=O)CN1CCN(CC1)C(C)=O)CC1=CC=C(CC(=O)OC)C=C1 BPZZWUMXCXBSHE-UHFFFAOYSA-N 0.000 claims 2
- UTDBMWAVSHBXLP-UHFFFAOYSA-N methyl 2-[4-[[[2-[(1-acetylpiperidin-4-yl)-methylamino]acetyl]-[3-(4-amino-2-butylimidazo[4,5-c]quinolin-1-yl)propyl]amino]methyl]phenyl]acetate Chemical compound CCCCC1=NC2=C(N)N=C3C=CC=CC3=C2N1CCCN(C(=O)CN(C)C1CCN(CC1)C(C)=O)CC1=CC=C(CC(=O)OC)C=C1 UTDBMWAVSHBXLP-UHFFFAOYSA-N 0.000 claims 2
- NIOHPZFOZHREKH-UHFFFAOYSA-N methyl 2-[4-[[acetyl-[3-(4-amino-2-butylimidazo[4,5-c]quinolin-1-yl)propyl]amino]methyl]phenyl]acetate Chemical compound CCCCC1=NC2=C(N)N=C3C=CC=CC3=C2N1CCCN(C(C)=O)CC1=CC=C(CC(=O)OC)C=C1 NIOHPZFOZHREKH-UHFFFAOYSA-N 0.000 claims 2
- 125000002950 monocyclic group Chemical group 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- RFIOZSIHFNEKFF-UHFFFAOYSA-M piperazine-1-carboxylate Chemical compound [O-]C(=O)N1CCNCC1 RFIOZSIHFNEKFF-UHFFFAOYSA-M 0.000 claims 2
- SRJOCJYGOFTFLH-UHFFFAOYSA-M piperidine-4-carboxylate Chemical compound [O-]C(=O)C1CCNCC1 SRJOCJYGOFTFLH-UHFFFAOYSA-M 0.000 claims 2
- 229920006395 saturated elastomer Polymers 0.000 claims 2
- 150000003573 thiols Chemical class 0.000 claims 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 claims 1
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 1
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 claims 1
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical class OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 claims 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 1
- 125000004406 C3-C8 cycloalkylene group Chemical group 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 206010048768 Dermatosis Diseases 0.000 claims 1
- 208000005176 Hepatitis C Diseases 0.000 claims 1
- 208000022361 Human papillomavirus infectious disease Diseases 0.000 claims 1
- 101001043818 Mus musculus Interleukin-31 receptor subunit alpha Proteins 0.000 claims 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 208000002205 allergic conjunctivitis Diseases 0.000 claims 1
- 230000000172 allergic effect Effects 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 208000024998 atopic conjunctivitis Diseases 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 125000002619 bicyclic group Chemical group 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 150000001720 carbohydrates Chemical class 0.000 claims 1
- 239000003638 chemical reducing agent Substances 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 claims 1
- 239000001530 fumaric acid Substances 0.000 claims 1
- 125000001188 haloalkyl group Chemical group 0.000 claims 1
- 208000002672 hepatitis B Diseases 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 229960002510 mandelic acid Drugs 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- XJRQEYKDFZPUDL-UHFFFAOYSA-N methyl 2-[3-[[3-(4-amino-2-butylimidazo[4,5-c]quinolin-1-yl)propyl-[2-(dimethylamino)acetyl]amino]methyl]phenyl]acetate Chemical compound CCCCC1=NC2=C(N)N=C3C=CC=CC3=C2N1CCCN(C(=O)CN(C)C)CC1=CC=CC(CC(=O)OC)=C1 XJRQEYKDFZPUDL-UHFFFAOYSA-N 0.000 claims 1
- JXQDWYKXXBRDST-UHFFFAOYSA-N methyl 2-[3-[[3-(4-amino-2-butylimidazo[4,5-c]quinolin-1-yl)propyl-[2-[4-(2-methoxyethyl)piperazin-1-yl]acetyl]amino]methyl]phenyl]acetate Chemical compound CCCCC1=NC2=C(N)N=C3C=CC=CC3=C2N1CCCN(C(=O)CN1CCN(CCOC)CC1)CC1=CC=CC(CC(=O)OC)=C1 JXQDWYKXXBRDST-UHFFFAOYSA-N 0.000 claims 1
- DMIPROXJBJIXPM-UHFFFAOYSA-N methyl 2-[3-[[4-[[4-amino-2-(2-methoxyethyl)imidazo[4,5-c]quinolin-1-yl]methyl]piperidin-1-yl]methyl]phenyl]acetate;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F.COCCC1=NC2=C(N)N=C3C=CC=CC3=C2N1CC(CC1)CCN1CC1=CC=CC(CC(=O)OC)=C1 DMIPROXJBJIXPM-UHFFFAOYSA-N 0.000 claims 1
- QZTUTIRJBODVLE-UHFFFAOYSA-N methyl 2-[4-[[3-(4-amino-2-butylimidazo[4,5-c]quinolin-1-yl)propyl-(2-morpholin-4-ylacetyl)amino]methyl]phenyl]acetate Chemical compound CCCCC1=NC2=C(N)N=C3C=CC=CC3=C2N1CCCN(C(=O)CN1CCOCC1)CC1=CC=C(CC(=O)OC)C=C1 QZTUTIRJBODVLE-UHFFFAOYSA-N 0.000 claims 1
- XHNJWZRQHYJISF-UHFFFAOYSA-N methyl 2-[4-[[3-(4-amino-2-butylimidazo[4,5-c]quinolin-1-yl)propyl-[2-(dimethylamino)ethyl]amino]methyl]phenyl]acetate Chemical compound CCCCC1=NC2=C(N)N=C3C=CC=CC3=C2N1CCCN(CCN(C)C)CC1=CC=C(CC(=O)OC)C=C1 XHNJWZRQHYJISF-UHFFFAOYSA-N 0.000 claims 1
- ZZHWWYPUQYIZCL-UHFFFAOYSA-N methyl 2-[4-[[3-[4-amino-2-(2-methoxyethyl)imidazo[4,5-c]quinolin-1-yl]propyl-(2-pyrrolidin-1-ylacetyl)amino]methyl]phenyl]acetate Chemical compound COCCC1=NC2=C(N)N=C3C=CC=CC3=C2N1CCCN(C(=O)CN1CCCC1)CC1=CC=C(CC(=O)OC)C=C1 ZZHWWYPUQYIZCL-UHFFFAOYSA-N 0.000 claims 1
- 150000002772 monosaccharides Chemical class 0.000 claims 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 230000000414 obstructive effect Effects 0.000 claims 1
- 230000001590 oxidative effect Effects 0.000 claims 1
- 239000001301 oxygen Chemical group 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 125000006239 protecting group Chemical group 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
- 239000012321 sodium triacetoxyborohydride Substances 0.000 claims 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 1
- 239000011593 sulfur Chemical group 0.000 claims 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Biotechnology (AREA)
- Ophthalmology & Optometry (AREA)
- Otolaryngology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Claims (19)
1. Spoj prema formuli (I)
[image]
pri čemu
R1 predstavlja ravnolančani C1-C6 alkil, proizvoljno supstituiran sa jednim ili više supstituenata neovisno odabranih od halogena, cijano, hidroksila i C1-C3 alkoksi;
Z1 predstavlja C2-C6 alkilen ili C3-C8 cikloalkilen skupinu;
X1 predstavlja NR5, >N-COR5, CONR5, NR5CO, SO2NR5, >N-SO2R5, NR5SO2, NR5CONR6 ili NR6CONR5, S(O)p ili O;
Y1 predstavlja jednostruku vezu ili C1-C6 alkilen;
svaki R2 je neovisno odabran od halogena, cijano, hidroksi, tiola, C1-C3 alkila, C1-C3 hidroksialkila, C1-C3 haloalkila, C1-C3 alkoksi, C1-C3 haloalkoksi, C1-3alkiltio, C1-3alkilsulfonila i C1-3alkilsulfinila;
R3 predstavlja C1-6alkil proizvoljno supstituiran sa C1-6alkoksi;
svaki Ra je neovisno odabran od halogena, cijano, hidroksi, tiola, C1-C3 alkila, C1-C3 hidroksialkila, C1-C3 haloalkila, C1-C3 alkoksi, C1-C3 haloalkoksi, C1-3alkiltio, C1-3alkilsulfonila i C1-3alkilsulfinila;
R5 predstavlja vodik, 3- do 8-člani zasićeni heterociklički prsten koji sadrži prstenastu skupinu O, S(O)p ili NR10, C1-C6 alkilnu skupinu ili C3-C6 cikloalkilnu skupinu, posljednje dvije skupine proizvoljno su supstituirane sa jednim ili više supstituenata neovisno odabranih od NR7R8 ili R9,
ili R5 je C1-C6 alkilen koji može biti povezan sa atomom ugljika u C2-C6alkilen skupini Z1 tako da tvori zasićeni 4-7 člani prsten koji sadrži dušik;
pod uvjetom da kada X1 je >N-SO2R5, R5 ne predstavlja vodik;
R7 i R8 svaki neovisno predstavljaju vodik, 3- do 8-člani zasićeni heterociklički prsten koji sadrži prstenastu skupinu O, S(O)p ili NR10a, C1-C6 alkil ili C3-C6 cikloalkil, posljednje dvije skupine proizvoljno su supstituirane sa jednom ili više skupina neovisno odabranih od halogena, cijano, S(O)qR11, OR12, CO2R12, OC(O)R12, SO2NR12R13, CONR12R13, NR12R13, NR12SO2R14, NR12COR13, ili 3- do 8-člani zasićeni heterociklički prsten koji sadrži prstenastu skupinu O, S(O)p ili NR10b,
ili R7 i R8 zajedno sa atomom dušika na koji su spojeni tvore 3- do 8-člani zasićeni heterociklički prsten koji sadrži atom dušika u prstenu i proizvoljno jedan ili više dodatnih heteroatoma neovisno odabranih od dušika, kisika, sumpora i sulfonila, te je heterociklički prsten proizvoljno supstituiran sa jednim ili više supstituenata neovisno odabranih od halogena, cijano, S(O)qR15, OR15, CO2R15, COR15, OC(O)R15, SO2NR15R16, CONR15R16, NR15R16, NR15SO2R17, NR15COR16, NR15CO2R16, heteroarila, C1-C6 haloalkila, C3-C8 cikloalkila i C1-C6 alkila, posljednje dvije skupine proizvoljno su supstituirane sa jednom ili više skupina neovisno odabranih od cijano, S(O)qR18 OR18, CO2R18 SO2NR18R19, CONR18R19 ili NR18R19.
R9 predstavlja halogen, cijano, CO2R20 S(O)qR20 OR20 SO2NR20R22, CONR20R22 NR20SO2R21, NR20CO2R21, NR20COR22 ili 3- do 8-člani zasićeni heterociklički prsten koji sadrži prstenastu skupinu NR10c;
R10, R10a, R10b i R10c neovisno predstavljaju vodik, CO2R23, S(O)qR23, COR24, ili C1-C6 alkil, C2-C6 alkenil, C2-C6 alkinil ili C3-C8 cikloalkilnu skupinu, od kojih svaka može biti proizvoljno supstituirana sa jednim ili više supstituenata neovisno odabranih od halogena, cijano, OR25 ili NR25R26;
R6, R11, R12, R13, R15, R16, R18, R19, R20, R22, R24, R25 i R26 svaki neovisno predstavlja vodik, C1-C6 alkil ili C3-C6 cikloalkil;
R14, R17, R21 i R23 svaki neovisno predstavlja C1-C6 alkil ili C3-C6 cikloalkil;
m, n, p i q svaki neovisno predstavlja cijeli broj 0, 1 ili 2; i
A predstavlja monociklički ili biciklički C6-C10 aril ili monocikličku ili bicikličku C5-C12 heteroarilnu skupinu koja sadrži 1-3 heteroatoma;
ili njegova farmaceutski prihvatljiva sol.
2. Spoj prema zahtjevu 1 naznačen time da R1 je metil.
3. Spoj prema zahtjevu 1 ili zahtjevu 2 naznačen time da Z1 je n-propilen.
4. Spoj prema bilo kojem od prethodnih zahtjeva naznačen time da X1 je skupina NR5 ili >NCOR5.
5. Spoj prema zahtjevu 4 naznačen time da X1 je >NCOR5.
6. Spoj prema zahtjevu 4 ili zahtjevu 5 naznačen time da R5 je vodik ili C1-C6 alkil proizvoljno supstituiran sa jednom ili više skupina NR7R8 ili R9 gdje su R7, R8 i R9 kako je definirano u zahtjevu 1.
7. Spoj prema zahtjevu 4 ili zahtjevu 5 naznačen time da R5 je C1-C6 alkilen koji može biti povezan sa atomom ugljika u C2-C6 alkilen skupini Z1 tako da tvori zasićeni 4-7 člani prsten koji sadrži dušik.
8. Spoj prema bilo kojem od prethodnih zahtjeva naznačen time da Y1 predstavlja C1-C6 alkilen.
9. Spoj prema bilo kojem od prethodnih zahtjeva naznačen time da A je fenil.
10. Spoj prema bilo kojem od prethodnih zahtjeva naznačen time da n je 0.
11. Spoj prema bilo kojem od prethodnih zahtjeva naznačen time da R3 je n-butil, metoksietil ili etoksimetil.
12. Spoj prema bilo kojem od prethodnih zahtjeva naznačen time da m je 0.
13. Spoj prema zahtjevu 1 naznačen time da je odabran od:
metil 2-(4-((3-(4-amino-2-butil-1H-imidazo[4,5-c]kinolin-1-il)propilamino)metil)fenil)acetat,
metil 2-(3-((3-(4-amino-2-butil-1H-imidazo[4,5-c]kinolin-1-il)propilamino)metil)fenil)acetat,
metil 2-(4-((N-(3-(4-amino-2-butil-1H-imidazo[4,5-c]kinolin-1-il)propil)-2-(dimetilamino)acetamido)metil)fenil)acetat,
metil 2-(3-((N-(3-(4-amino-2-butil-1H-imidazo[4,5-c]kinolin-1-il)propil)-2-(dimetilamino)acetamido)metil)fenil)acetat,
metil 2-(3-((4-((4-amino-2-(2-metoksietil)-1H-imidazo[4,5-c]kinolin-1-il)metil)piperidin-1-il)metil)fenil)acetat di-trifluoroacetatna sol,
metil [4-(1[3-(4-amino-2-butil-1H-imidazo[4,5-c]kinolin-1-il)propil][2-(dimetilamino)etil] amino}metil)fenil] acetat,
metil 2-(3-((N-(3-(4-amino-2-(etoksimetil)-1H-imidazo[4,5-c]kinolin-1-il)propil)-2-(dimetilamino)acetamido)metil)fenil)acetat,
metil 2-(3-(((3-(4-amino-2-butil-1H-imidazo[4,5-c]kinolin-1-il)propil)(1-metilpiperidin-4-il)amino)metil)fenil)acetat,
metil 2-(4-(((3-(4-amino-2-butil-1H-imidazo[4,5-c]kinolin-1-il)propil)(1-metilpiperidin-4-il)amino)metil)fenil)acetat,
metil 2-(4-((N-(3-(4-amino-2-butil-1H-imidazo[4,5-c]kinolin-1-il)propil)-2-(4-metilpiperazin-1-il)acetamido)metil)fenil)acetat,
metil 2-(3-(((3-(4-amino-2-butil-1H-imidazo[4,5-c]kinolin-1-il)propil)(3-(dimetilamino)propil)amino)metil)fenil)acetat,
metil 2-(3-(((3-(4-amino-2-butil-1H-imidazo[4,5-c]kinolin-1-il)propil)(3-morfolinopropil)amino)metil)fenil)acetat,
metil 2-(3-(((3-(4-amino-2-butil-1H-imidazo[4,5-c]kinolin-1-il)propil)(3-(etil(metil)amino)propil)amino)metil)fenil)acetat,
metil 2-(3-(((3-(4-amino-2-butil-1H-imidazo[4,5-c]kinolin-1-il)propil)(3-(4-metilpiperazin-1-il)propil)amino)metil)fenil)acetat,
metil 2-(4-((N-(3-(4-amino-2-butil-1H-imidazo[4,5-c]kinolin-1-il)propil)-2-(metilsulfonil)acetamido)metil)fenil)acetat,
metil 2-(4-((N-(3-(4-amino-2-butil-1H-imidazo[4,5-c]kinolin-1-il)propil)acetamido)metil)fenil)acetat,
metil 2-(4-((N-(3-(4-amino-2-butil-1H-imidazo[4,5-c]kinolin-1-il)propil)-2-morfolinoacetamido)metil)fenil)acetat,
metil 2-(4-((N-(3-(4-amino-2-butil-1H-imidazo[4,5-c]kinolin-1-il)propil)-2-((2-metoksietil)(metil)amino)acetamido)metil)fenil)acetat,
metil 2-(4-((2-(4-acetilpiperazin-1-il)-N-(3-(4-amino-2-butil-1H-imidazo[4,5-c]kinolin-1-il)propil)acetamido)metil)fenil)acetat,
(R)-metil 2-(4-((N-(3-(4-amino-2-butil-1H-imidazo[4,5-c]kinolin-1-il)propil)-2-(3-hidroksipirolidin-1-il)acetamido)metil)fenil)acetat,
metil 2-(4-((N-(3-(4-amino-2-butil-1H-imidazo[4,5-c]kinolin-1-il)propil)-2-(4-(pirimidin-2-il)piperazin-1-il)acetamido)metil)fenil)acetat,
etil 4-(2-((3-(4-amino-2-butil-1H-imidazo[4,5-c]kinolin-1-il)propil)(4-(2-metoksi-2-oksoetil)benzil)amino)-2-oksoetil)piperazin-1-karboksilat,
metil 2-(4-((N-(3-(4-amino-2-butil-1H-imidazo[4,5-c]kinolin-1-il)propil)-2-(4-(etilsulfonil)piperazin-1-il)acetamido)metil)fenil)acetat,
metil 2-(4-((N-(3-(4-amino-2-butil-1H-imidazo[4,5-c]kinolin-1-il)propil)-2-(piperidin-1-il)acetamido)metil)fenil)acetat,
metil 2-(4-((N-(3-(4-amino-2-butil-1H-imidazo[4,5-c]kinolin-1-il)propil)-2-(4-(tert-butoksikarbonilamino)piperidin-1-il)acetamido)metil)fenil)acetat,
metil 2-(4-((N-(3-(4-amino-2-butil-1H-imidazo[4,5-c]kinolin-1-il)propil)-2-(4-(tert-butoksikarbonil(metil)amino)piperidin-1-il)acetamido)metil)fenil)acetat,
etil 2-(1-(2-((3-(4-amino-2-butil-1H-imidazo[4,5-c]kinolin-1-il)propil)(4-(2-metoksi-2-oksoetil)benzil)amino)-2-oksoetil)piperidin-4-il)acetat,
metil 1-(2-((3-(4-amino-2-butil-1H-imidazo[4,5-c] kinolin-1-il)propil)(4-(2-metoksi-2-oksoetil)benzil)amino)-2-oksoetil)piperidine-4-karboksilat,
metil 2-(4-((N-(3-(4-amino-2-(2-metoksietil)-1H-imidazo[4,5-c]kinolin-1-il)propil)-2-(piperidin-1-il)acetamido)metil)fenil)acetat,
metil 2-(4-((N-(3-(4-amino-2-(2-metoksietil)-1H-imidazo[4,5-c]kinolin-1-il)propil)-2-(dimetilamino)acetamido)metil)fenil)acetat,
metil 2-(3-((N-(3-(4-amino-2-(2-metoksietil)-1H-imidazo[4,5-c]kinolin-1-il)propil)-2-(piperidin-1-il)acetamido)metil)fenil)acetat,
metil 2-(4-((N-(3-(4-amino-2-(2-metoksietil)-1H-imidazo[4,5-c]kinolin-1-il)propil)-2-((2-metoksietil)(metil)amino)acetamido)metil)fenil)acetat,
metil 2-(4-((N-(3-(4-amino-2-(2-metoksietil)-1H-imidazo[4,5-c]kinolin-1-il)propil)-3-(piperidin-1-il)propanamido)metil)fenil)acetat,
metil 2-(4-(((3-(4-amino-2-(2-metoksietil)-1H-imidazo[4,5-c]kinolin-1-il)propil)(3-morfolinopropil)amino)metil)fenil)acetat,
(S)-metil 2-(4-((N-(3-(4-amino-2-(2-metoksietil)-1H-imidazo[4,5-c]kinolin-1-il)propil)-2-(2-(metoksimetil)pirolidin-1-il)acetamido)metil)fenil)acetat,
(R)-metil 2-(4-((N-(3-(4-amino-2-(2-metoksietil)-1H-imidazo[4,5-c]kinolin-1-il)propil)-2-(2-(metoksimetil)pirolidin-1-il)acetamido)metil)fenil)acetat,
metil 2-(4-((N-(3-(4-amino-2-(2-metoksietil)-1H-imidazo[4,5-c]kinolin-1-il)propil)-2-(pirolidin-1-il)acetamido)metil)fenil)acetat,
metil 2-(4-((N-(3-(4-amino-2-(2-metoksietil)-1H-imidazo[4,5-c]kinolin-1-il)propil)-2-((2-hidroksietil)(metil)amino)acetamido)metil)fenil)acetat,
metil 2-(3-((N-(3-(4-amino-2-butil-1H-imidazo[4,5-c]kinolin-1-il)propil)-2-((2-metoksietil)(metil)amino)acetamido)metil)fenil)acetat,
metil 2-(3-((N-(3-(4-amino-2-butil-1H-imidazo[4,5-c]kinolin-1-il)propil)-2-(butil(metil)amino)acetamido)metil)fenil)acetat,
metil 3-((N-(3-(4-amino-2-butil-1H-imidazo[4,5-c]kinolin-1-il)propil)-2-(dipropilamino)acetamido)metil)fenil)acetat,
metil 2-(3-((N-(3-(4-amino-2-butil-1H-imidazo[4,5-c]kinolin-1-il)propil)-2-(bis(2-hidroksietil)amino)acetamido)metil)fenil)acetat,
metil 2-(3-((N-(3-(4-amino-2-butil-1H-imidazo[4,5-c]kinolin-1-il)propil)-2-(metil(tetrahidro-2H-piran-4-il)amino)acetamido)metil)fenil)acetat,
metil 2-(3-((N-(3-(4-amino-2-butil-1H-imidazo[4,5-c]kinolin-1-il)propil)-2-(azetidin-1-il)acetamido)metil)fenil)acetat,
metil 2-(3-((N-(3-(4-amino-2-butil-1H-imidazo[4,5-c]kinolin-1-il)propil)-2-(3-hidroksiazetidin-1-il)acetamido)metil)fenil)acetat,
metil 2-(3-((N-(3-(4-amino-2-butil-1H-imidazo[4,5-c]kinolin-1-il)propil)-2-(pirolidin-1-il)acetamido)metil)fenil)acetat,
metil 2-(3-((N-(3-(4-amino-2-butil-1H-imidazo[4,5-c]kinolin-1-il)propil)-2-(3-hidroksipirolidin-1-il)acetamido)metil)fenil)acetat,
(R)-metil 2-(3-((N-(3-(4-amino-2-butil-1H-imidazo[4,5-c]kinolin-1-il)propil)-2-(3-hidroksipirolidin-1-il)acetamido)metil)fenil)acetat,
metil 2-(3-((N-(3-(4-amino-2-butil-1H-imidazo[4,5-c]kinolin-1-il)propil)-2-(piperidin-1-il)acetamido)metil)fenil)acetat,
metil 2-(3-((N-(3-(4-amino-2-butil-1H-imidazo[4,5-c]kinolin-1-il)propil)-2-(4-hidroksipiperidin-1-il)acetamido)metil)fenil)acetat,
metil 2-(3-((N-(3-(4-amino-2-butil-1H-imidazo[4,5-c]kinolin-1-il)propil)-2-(4-metoksipiperidin-1-il)acetamido)metil)fenil)acetat,
metil 2-(3-((N-(3-(4-amino-2-butil-1H-imidazo[4,5-c]kinolin-1-il)propil)-2-(4-(dimetilkarbamoil)piperidin-1-il)acetamido)metil)fenil)acetat,
metil 2-(3-((N-(3-(4-amino-2-butil-1H-imidazo[4,5-c]kinolin-1-il)propil)-2-morfolinoacetamido)metil)fenil)acetat,
metil 2-(3-((N-(3-(4-amino-2-butil-1H-imidazo[4,5-c]kinolin-1-il)propil)-2-((2S,6R)-2,6-dimetilmorfolino)acetamido)metil)fenil)acetat,
metil 2-(3-((N-(3-(4-amino-2-butil-1H-imidazo[4,5-c]kinolin-1-il)propil)-2-(4-metilpiperazin-1-il)acetamido)metil)fenil)acetat,
metil 2-(3-((N-(3-(4-amino-2-butil-1H-imidazo[4,5-c]kinolin-1-il)propil)-2-(4-(2-hidroksietil)piperazin-1-il)acetamido)metil)fenil)acetat,
metil 2-(3-((N-(3-(4-amino-2-butil-1H-imidazo[4,5-c]kinolin-1-il)propil)-2-(4-(2-metoksietil)piperazin-1-il)acetamido)metil)fenil)acetat,
metil 2-(3-((2-(4-acetilpiperazin-1-il)-N-(3-(4-amino-2-butil-1H-imidazo[4,5-c]kinolin-1-il)propil)acetamido)metil)fenil)acetat,
metil 2-(3-((N-(3-(4-amino-2-butil-1H-imidazo[4,5-c]kinolin-1-il)propil)-2-(4-(metilsulfonil)piperazin-1-il)acetamido)metil)fenil)acetat,
metil 2-(3-((N-(3-(4-amino-2-butil-1H-imidazo[4,5-c]kinolin-1-il)propil)-2-(azepan-1-il)acetamido)metil)fenil)acetat,
metil 2-(3-((N-(3-(4-amino-2-butil-1H-imidazo[4,5-c]kinolin-1-il)propil)-2-(1,4-oksazepan-4-il)acetamido)metil)fenil)acetat,
metil 2-(3-((N-(3-(4-amino-2-butil-1H-imidazo[4,5-c]kinolin-1-il)propil)-2-(4-metil-1,4-diazepan-1-il)acetamido)metil)fenil)acetat,
metil 2-(3-((2-(4-acetil-1,4-diazepan-1-il)-N-(3-(4-amino-2-butil-1H-imidazo[4,5-c]kinolin-1-il)propil)acetamido)metil)fenil)acetat,
metil 2-(3-((N-(3-(4-amino-2-butil-1H-imidazo[4,5-c]kinolin-1-il)propil)-2-(4-(etilkarbamoil)-1,4-diazepan-1-il)acetamido)metil)fenil)acetat,
metil 2-(3-((N-(3-(4-amino-2-butil-1H-imidazo[4,5-c]kinolin-1-il)propil)-2-(4-(metilsulfonil)-1,4-diazepan-1-il)acetamido)metil)fenil)acetat,
metil 2-(4-((N-(3-(4-amino-2-butil-1H-imidazo[4,5-c]kinolin-1-il)propil)-2-(4-(2-metoksietil)piperazin-1-il)acetamido)metil)fenil)acetat,
metil 2-(4-((2-(4-acetil-1,4-diazepan-1-il)-N-(3-(4-amino-2-butil-1H-imidazo[4,5-c]kinolin-1-il)propil)acetamido)metil)fenil)acetat,
metil 2-(4-((N-(3-(4-amino-2-butil-1H-imidazo[4,5-c]kinolin-1-il)propil)-2-(4-(metilsulfonil)-1,4-diazepan-1-il)acetamido)metil)fenil)acetat,
metil 2-(4-((2-((1-acetilpiperidin-4-il)(metil)amino)-N-(3-(4-amino-2-butil-1H-imidazo[4,5-c]kinolin-1-il)propil)acetamido)metil)fenil)acetat,
metil 2-(4-((N-(3-(4-amino-2-(2-metoksietil)-1H-imidazo[4,5-c]kinolin-1-il)propil)-2-(4-metilpiperazin-1-il)acetamido)metil)fenil)acetat,
metil 2-(4-((N-(3-(4-amino-2-(2-metoksietil)-1H-imidazo[4,5-c]kinolin-1-il)propil)-2-(4-(2-metoksietil)piperazin-1-il)acetamido)metil)fenil)acetat,
metil 2-(3-((N-(3-(4-amino-2-(2-metoksietil)-1H-imidazo[4,5-c]kinolin-1-il)propil)-2-(4-metilpiperazin-1-il)acetamido)metil)fenil)acetat, i
metil 2-(3-((N-(3-(4-amino-2-(2-metoksietil)-1H-imidazo[4,5-c]kinolin-1-il)propil)-2-(4-(2-metoksietil)piperazin-1-il)acetamido)metil)fenil)acetat; ili
farmaceutski prihvatljiva sol bilo kojeg od njih
14. Spoj prema zahtjevu 1 naznačen time da je odabran od:
metil 2-(4-((3-(4-amino-2-butil-1 H-imidazo[4,5-c]kinolin-1-il)propilamino)metil)fenil)acetat,
metil 2-(3-((3-(4-amino-2-butil-1H-imidazo[4,5-c]kinolin-1-il)propilamino)metil)fenil)acetat,
metil 2-(4-((N-(3-(4-amino-2-butil-1H-imidazo[4,5-c]kinolin-1-il)propil)-2-(dimetilamino)acetamido)metil)fenil)acetat,
metil 2-(3-((N-(3-(4-amino-2-butil-1H-imidazo[4,5-c]kinolin-1-il)propil)-2-(dimetilamino)acetamido)metil)fenil)acetat,
di-trifluoroacetatna sol metil 2-(3-((4-((4-amino-2-(2-metoksietil)-1H-imidazo[4,5-c]kinolin-1-il)metil)piperidin-1-il)metil)fenil)acetata,
metil [4-({[3-(4-amino-2-butil-1H-imidazo[4,5-c]kinolin-1-il)propil][2-(dimetilamino)etil]amino}metil)fenil]acetat,
metil 2-(3-((N-(3-(4-amino-2-(etoksimetil)-1H-imidazo[4,5-c]kinolin-1-il)propil)-2-(dimetilamino)acetamido)metil)fenil)acetat,
metil 2-(3-(((3-(4-amino-2-butil-1H-imidazo[4,5-c]kinolin-1-il)propil)(1-metilpiperidin-4-il)amino)metil)fenil)acetat,
metil 2-(4-(((3-(4-amino-2-butil-1H-imidazo[4,5-c]kinolin-1-il)propil)(1-metilpiperidin-4-il)amino)metil)fenil)acetat,
metil 2-(4-((N-(3-(4-amino-2-butil-1H-imidazo[4,5-c]kinolin-1-il)propil)-2-(4-metilpiperazin-1-il)acetamido)metil)fenil)acetat,
metil 2-(3-(((3-(4-amino-2-butil-1H-imidazo[4,5-c]kinolin-1-il)propil)(3-(dimetilamino)propil)amino)metil)fenil)acetat,
metil 2-(3-(((3-(4-amino-2-butil-1H-imidazo[4,5-c]kinolin-1-il)propil)(3-morfolinopropil)amino)metil)fenil)acetat,
metil 2-(3-(((3-(4-amino-2-butil-1H-imidazo[4,5-c]kinolin-1-il)propil)(3-(etil(metil)amino)propil)amino)metil)fenil)acetat,
metil 2-(3-(((3-(4-amino-2-butil-1H-imidazo[4,5-c]kinolin-1-il)propil)(3-(4-metilpiperazin-1-il)propil)amino)metil)fenil)acetat,
metil 2-(4-((N-(3-(4-amino-2-butil-1H-imidazo[4,5-c]kinolin-1-il)propil)-2-(metilsulfonil)acetamido)metil)fenil)acetat,
metil 2-(4-((N-(3-(4-amino-2-butil-1H-imidazo[4,5-c]kinolin-1-il)propil)acetamido)metil)fenil)acetat,
metil 2-(4-((N-(3-(4-amino-2-butil-1 H-imidazo [4,5-c]kinolin-1-il)propil)-2-morfolinoacetamido)metil)fenil)acetat,
metil 2-(4-((N-(3-(4-amino-2-butil-1H-imidazo[4,5-c]kinolin-1-il)propil)-2-((2-metoksietil)(metil)amino)acetamido)metil)fenil)acetat,
metil 2-(4-((2-(4-acetilpiperazin-1-il)-N-(3-(4-amino-2-butil-1H-imidazo[4,5-c]kinolin-1-il)propil)acetamido)metil)fenil)acetat,
(R)-metil 2-(4-((N-(3-(4-amino-2-butil-1H-imidazo[4,5-c]kinolin-1-il)propil)-2-(3-hidroksipirolidin-1-il)acetamido)metil)fenil)acetat,
metil 2-(4-((N-(3-(4-amino-2-butil-1H-imidazo[4,5-c]kinolin-1-il)propil)-2-(4-(pirimidin-2-il)piperazin-1-il)acetamido)metil)fenil)acetat,
etil 4-(2-((3-(4-amino-2-butil-1H-imidazo[4,5-c]kinolin-1-il)propil)(4-(2-metoksi-2-oksoetil)benzil)amino)-2-oksoetil)piperazin-1-karboksilat,
metil 2-(4-((N-(3-(4-amino-2-butil-1H-imidazo[4,5-c]kinolin-1-il)propil)-2-(4-(etilsulfonil)piperazin-1-il)acetamido)metil)fenil)acetat,
metil 2-(4-((N-(3-(4-amino-2-butil-1H-imidazo[4,5-c]kinolin-1-il)propil)-2-(piperidin-1-il)acetamido)metil)fenil)acetat,
metil 2-(4-((N-(3-(4-amino-2-butil-1H-imidazo[4,5-c]kinolin-1-il)propil)-2-(4-(tert-butoksikarbonilamino)piperidin-1-il)acetamido)metil)fenil)acetat,
metil 2-(4-((N-(3-(4-amino-2-butil-1H-imidazo[4,5-c]kinolin-1-il)propil)-2-(4-(tert-butoksikarbonil(metil)amino)piperidin-1-il)acetamido)metil)fenil)acetat,
etil 2-(1-(2-((3-(4-amino-2-butil-1H-imidazo[4,5-c]kinolin-1-il)propil)(4-(2-metoksi-2-oksoetil)benzil)amino)-2-oksoetil)piperidin-4-il)acetat,
metil 1-(2-((3-(4-amino-2-butil-1H-imidazo[4,5-c]kinolin-1-il)propil)(4-(2-metoksi-2-oksoetil)benzil)amino)-2-oksoetil)piperidine-4-karboksilat,
metil 2-(4-((N-(3-(4-amino-2-(2-metoksietil)-1H-imidazo[4,5-c]kinolin-1-il)propil)-2-(piperidin-1-il)acetamido)metil)fenil)acetat,
metil 2-(4-((N-(3-(4-amino-2-(2-metoksietil)-1H-imidazo[4,5-c]kinolin-1-il)propil)-2-(dimetilamino)acetamido)metil)fenil)acetat,
saharidna sol metil 2-(3-((N-(3-(4-amino-2-(2-metoksietil)-1H-imidazo[4,5-c]kinolin-1-il)propil)-2-(piperidin-1-il)acetamido)metil)fenil)acetata,
metil 2-(4-((N-(3-(4-amino-2-(2-metoksietil)-1H-imidazo[4,5-c]kinolin-1-il)propil)-2-((2-metoksietil)(metil)amino)acetamido)metil)fenil)acetat,
metil 2-(4-((N-(3-(4-amino-2-(2-metoksietil)-1H-imidazo[4,5-c]kinolin-1-il)propil)-3-(piperidin-1-il)propanamido)metil)fenil)acetat,
metil 2-(4-(((3-(4-amino-2-(2-metoksietil)-1H-imidazo[4,5-c]kinolin-1-il)propil)(3-morfolinopropil)amino)metil)fenil)acetat,
disaharidna sol (S)-metil 2-(4-((N-(3-(4-amino-2-(2-metoksietil)-1H-imidazo[4,5-c]kinolin-1-il)propil)-2-(2-(metoksimetil)pirolidin-1-il)acetamido)metil)fenil)acetata,
disaharidna sol (R)-metil 2-(4-((N-(3-(4-amino-2-(2-metoksietil)-1H-imidazo[4,5-c]kinolin-1-il)propil)-2-(2-(metoksimetil)pirolidin-1-il)acetamido)metil)fenil)acetata,
disaharidna sol metil 2-(4-((N-(3-(4-amino-2-(2-metoksietil)-1H-imidazo[4,5-c]kinolin-1-il)propil)-2-(pirolidin-1-il)acetamido)metil)fenil)acetata,
disaharidna sol metil 2-(4-((N-(3-(4-amino-2-(2-metoksietil)-1H-imidazo[4,5-c]kinolin-1-il)propil)-2-((2-hidroksietil)(metil)amino)acetamido)metil)fenil)acetata,
metil 2-(3-((N-(3-(4-amino-2-butil-1H-imidazo[4,5-c]kinolin-1-il)propil)-2-((2-metoksietil)(metil)amino)acetamido)metil)fenil)acetat,
metil 2-(3-((N-(3-(4-amino-2-butil-1H-imidazo[4,5-c]kinolin-1-il)propil)-2-(butil(metil)amino)acetamido)metil)fenil)acetat,
metil 3-((N-(3-(4-amino-2-butil-1H-imidazo[4,5-c]kinolin-1-il)propil)-2-(dipropilamino)acetamido)metil)fenil)acetat,
metil 2-(3-((N-(3-(4-amino-2-butil-1H-imidazo[4,5-c]kinolin-1-il)propil)-2-(bis(2-hidroksietil)amino)acetamido)metil)fenil)acetat,
metil 2-(3-((N-(3-(4-amino-2-butil-1H-imidazo[4,5-c]kinolin-1-il)propil)-2-(metil(tetrahidro-2H-piran-4-il)amino)acetamido)metil)fenil)acetat,
metil 2-(3-((N-(3-(4-amino-2-butil-1H-imidazo[4,5-c]kinolin-1-il)propil)-2-(azetidin-1-il)acetamido)metil)fenil)acetat,
metil 2-(3-((N-(3-(4-amino-2-butil-1H-imidazo[4,5-c]kinolin-1-il)propil)-2-(3-hidroksiazetidin-1-il)acetamido)metil)fenil)acetat,
metil 2-(3-((N-(3-(4-amino-2-butil-1H-imidazo[4,5-c]kinolin-1-il)propil)-2-(pirolidin-1-il)acetamido)metil)fenil)acetat,
metil 2-(3-((N-(3-(4-amino-2-butil-1H-imidazo[4,5-c]kinolin-1-il)propil)-2-(3-hidroksipirolidin-1-il)acetamido)metil)fenil)acetat,
(R)-metil 2-(3-((N-(3-(4-amino-2-butil-1H-imidazo[4,5-c]kinolin-1-il)propil)-2-(3-hidroksipirolidin-1-il)acetamido)metil)fenil)acetat,
metil 2-(3-((N-(3-(4-amino-2-butil-1H-imidazo[4,5-c]kinolin-1-il)propil)-2-(piperidin-1-il)acetamido)metil)fenil)acetat,
metil 2-(3-((N-(3-(4-amino-2-butil-1H-imidazo[4,5-c]kinolin-1-il)propil)-2-(4-hidroksipiperidin-1-il)acetamido)metil)fenil)acetat,
metil 2-(3-((N-(3-(4-amino-2-butil-1H-imidazo[4,5-c]kinolin-1-il)propil)-2-(4-metoksipiperidin-1-il)acetamido)metil)fenil)acetat,
metil 2-(3-((N-(3-(4-amino-2-butil-1H-imidazo[4,5-c]kinolin-1-il)propil)-2-(4-(dimetilkarbamoil)piperidin-1-il)acetamido)metil)fenil)acetat,
metil 2-(3-((N-(3-(4-amino-2-butil-1H-imidazo[4,5-c]kinolin-1-il)propil)-2-morfolinoacetamido)metil)fenil)acetat,
metil 2-(3-((N-(3-(4-amino-2-butil-1H-imidazo[4,5-c]kinolin-1-il)propil)-2-((2S,6R)-2,6-dimetilmorfolino)acetamido)metil)fenil)acetat,
metil 2-(3-((N-(3-(4-amino-2-butil-1H-imidazo[4,5-c]kinolin-1-il)propil)-2-(4-metilpiperazin-1-il)acetamido)metil)fenil)acetat,
metil 2-(3-((N-(3-(4-amino-2-butil-1H-imidazo[4,5-c]kinolin-1-il)propil)-2-(4-(2-hidroksietil)piperazin-1-il)acetamido)metil)fenil)acetat,
metil 2-(3-((N-(3-(4-amino-2-butil-1 H-imidazo[4,5-c]kinolin-1-il)propil)-2-(4-(2-metoksietil)piperazin-1-il)acetamido)metil)fenil)acetat,
metil 2-(3-((2-(4-acetilpiperazin-1-il)-N-(3-(4-amino-2-butil-1H-imidazo[4,5-c]kinolin-1-il)propil)acetamido)metil)fenil)acetat,
metil 2-(3-((N-(3-(4-amino-2-butil-1H-imidazo[4,5-c]kinolin-1-il)propil)-2-(4-(metilsulfonil)piperazin-1-il)acetamido)metil)fenil)acetat,
metil 2-(3-((N-(3-(4-amino-2-butil-1H-imidazo[4,5-c]kinolin-1-il)propil)-2-(azepan-1-il)acetamido)metil)fenil)acetat,
metil 2-(3-((N-(3-(4-amino-2-butil-1H-imidazo[4,5-c]kinolin-1-il)propil)-2-(1,4-oksazepan-4-il)acetamido)metil)fenil)acetat,
metil 2-(3-((N-(3-(4-amino-2-butil-1H-imidazo[4,5-c]kinolin-1-il)propil)-2-(4-metil-1,4-diazepan-1-il)acetamido)metil)fenil)acetat,
metil 2-(3-((2-(4-acetil-1,4-diazepan-1-il)-N-(3-(4-amino-2-butil-H-imidazo[4,5-c]kinolin-1-il)propil)acetamido)metil)fenil)acetat,
metil 2-(3-((N-(3-(4-amino-2-butil-1H-imidazo[4,5-c]kinolin-1-il)propil)-2-(4-(etilkarbamoil)-1,4-diazepan-1-il)acetamido)metil)fenil)acetat,
metil 2-(3-((N-(3-(4-amino-2-butil-1H-imidazo[4,5-c]kinolin-1-il)propil)-2-(4-(metilsulfonil)-1,4-diazepan-1-il)acetamido)metil)fenil)acetat,
metil 2-(4-((N-(3-(4-amino-2-butil-1H-imidazo[4,5-c]kinolin-1-il)propil)-2-(4-(2-metoksietil)piperazin-1-il)acetamido)metil)fenil)acetat,
metil 2-(4-((2-(4-acetil-1,4-diazepan-1-il)-N-(3-(4-amino-2-butil-1H-imidazo[4,5-c]kinolin-1-il)propil)acetamido)metil)fenil)acetat,
metil 2-(4-((N-(3-(4-amino-2-butil-1H-imidazo[4,5-c]kinolin-1-il)propil)-2-(4-(metilsulfonil)-1,4-diazepan-1-il)acetamido)metil)fenil)acetat,
metil 2-(4-((2-((1-acetilpiperidin-4-il)(metil)amino)-N-(3-(4-amino-2-butil-1H-imidazo[4,5-c]kinolin-1-il)propil)acetamido)metil)fenil)acetat,
sol metil 2-(4-((N-(3-(4-amino-2-butil-1H-imidazo[4,5-c]kinolin-1-il)propil)-2-(dimetilamino)acetamido)metil)fenil)acetata dimetan sulfonske kiseline,
monosaharidna sol metil 2-(4-((N-(3-(4-amino-2-butil-1H-imidazo[4,5-c]kinolin-1-il)propil)-2-(dimetilamino)acetamido)metil)fenil)acetata,
disaharidna sol metil 2-(4-((N-(3-(4-amino-2-butil-1H-imidazo[4,5-c]kinolin-1-il)propil)-2-(dimetilamino)acetamido)metil)fenil)acetata,
sol metil 2-(4-((N-(3-(4-amino-2-butil-1H-imidazo[4,5-c]kinolin-1-il)propil)-2-(dimetilamino)acetamido)metil)fenil)acetata di-1-hidroksi-2-naftoične kiseline,
sol metil 2-(4-((N-(3-(4-amino-2-butil-1H-imidazo[4,5-c]kinolin-1-il)propil)-2-(dimetilamino)acetamido)metil)fenil)acetata dibenzensulfonske kiseline,
sol metil 2-(4-((N-(3-(4-amino-2-butil-1H-imidazo[4,5-c]kinolin-1-il)propil)-2-(dimetilamino)acetamido)metil)fenil)acetata bademove kiseline,
sol metil 2-(4-((N-(3-(4-amino-2-butil-1H-imidazo[4,5-c]kinolin-1-il)propil)-2-(dimetilamino)acetamido)metil)fenil)acetata fumarne kiseline,
metil 2-(4-((N-(3-(4-amino-2-(2-metoksietil)-1H-imidazo[4,5-c]kinolin-1-il)propil)-2-(4-metilpiperazin-1-il)acetamido)metil)fenil)acetat,
metil 2-(4-((N-(3-(4-amino-2-(2-metoksietil)-1H-imidazo[4,5-c]kinolin-1-il)propil)-2-(4-(2-metoksietil)piperazin-1-il)acetamido)metil)fenil)acetat,
metil 2-(3-((N-(3-(4-amino-2-(2-metoksietil)-1H-imidazo[4,5-c]kinolin-1-il)propil)-2-(4-metilpiperazin-1-il)acetamido)metil)fenil)acetat, i
metil 2-(3-((N-(3-(4-amino-2-(2-metoksietil)-1H-imidazo[4,5-c]kinolin-1-il)propil)-2-(4-(2-metoksietil)piperazin-1-il)acetamido)metil)fenil)acetat.
15. Postupak za dobivanje spoja prema formuli (I) ili njegove farmaceutski prihvatljive soli kako je gore definirano naznačen time da se sastoji bilo od:
(a) gdje X1 je skupina NR5, reakcijom spoja sa formulom (II)
[image]
pri čemu Z1, R3, Ra i m su kako je definirano u formuli (I) i L1 je odlazeća skupina, sa spojem prema formuli (III)
[image]
gdje Y1, R1, R2, R5, A i n su kako je definirano u formuli (I); ili
(b) gdje X1 je skupina NR5 i Y1 je C1-C6 alkilen, reakcijom spoja sa formulom (IV)
[image]
gdje Ra, R3, R5, Z1 i m su kako je definirano u formuli (I), sa spojem sa formulom (V)
[image]
gdje R1, R2, A i n su kako je definirano u formuli (I) i Y2 je veza ili C1-5alkilenska skupina u prisutnosti pogodnog redukcijskog sredstva (npr. natrijevog triacetoksiborohidrida); ili
(c) gdje X1 je skupina NR5, O ili S, reakcijom spoja sa formulom (VI)
[image]
pri čemu X3 je skupina NR5, O ili S, i Z1, R3, R5, Ra i m su kako je definirano u formuli (I), sa spojem sa formulom (VII)
[image]
gdje Y1, R1, R2, A i n su kako je definirano u formuli (I) i L2 je odlazeća skupina; ili
(d) gdje X1 je skupina S(O)p gdje p je 1 ili 2, oksidacijom spoja sa formulom (I) gdje X1 je S; ili
(e) gdje X1 je skupina NR5CO, NR5SO2, NR5CONR6 ili NR6CONR5, reakcijom spoja sa formulom (IVA)
[image]
gdje Ra, R3, Z1 i m su kako je definirano u odnosu na formulu (I) i R5a je skupina R5 ili R6 kako je definirano u odnosu na formulu (I),
sa spojem sa formulom (VIII)
[image]
gdje L3 je odlazeća skupina kao što je halo, X2 je CO, SO2, CONR6 ili CONR5 skupina u tom poretku, i Y1, R1, R2, A i n su kako je definirano u odnosu na formulu (I); ili
(f) gdje X1 je CONR5 ili SO2NR5, reakcijom spoja sa formulom (IX)
[image]
gdje X4 je aktivirana kiselina kao što je kiseli klorid ili SO2Cl, Ra, R3, Z1 i m su kako je definirano u formuli (I), sa spojem sa formulom (III) kako je gore definirano; ili
(h) gdje X1 je >N-COR5 ili >N-SO2R5, reakcijom spoja prema formuli (I) gdje X1 je NR5 gdje R5 je vodik sa spojem prema formuli (X) ili (XI) u tom poretku
L4-COR5 (X)
L4-SO2R5 (XI)
gdje L4 je odlazeća skupina kao što je halo ili kloro, a R5 je definiran u odnosu na formulu (I);
te zatim ako se želi ili ako je potrebno, provođenje jednog ili više slijedećih koraka:
pretvaranje dobivenog spoja u drugi spoj formule (I);
uklanjanje bilo kojih zaštitnih skupina;
formiranje farmaceutski prihvatljive soli tog spoja.
16. Farmaceutski pripravak naznačen time da sadrži spoj prema formuli (I) ili njegovu farmaceutski prihvatljivu sol prema bilo kojem od zahtjeva 1 do 14 u kombinaciji sa farmaceutski prihvatljivim adjuvantom, razrjeđivačem ili nosačem.
17. Spoj prema formuli (I) ili njegova farmaceutski prihvatljiva sol prema bilo kojem od zahtjeva 1 do 14 naznačen time da je za uporabu kod liječenja alergijskih ili virusnih bolesti ili karcinoma ili za uporabu kod liječenja astme, COPD, alergijskog rinitisa, alergijskog konjunktivitisa, atopijskog dermatitisa, raka, hepatitisa B, hepatitisa C, HIV, HPV, bakterijskih infekcija i dermatoze.
18. Spoj prema formuli (I) ili njegova farmaceutski prihvatljiva sol prema bilo kojem od zahtjeva 1 do 14 naznačen time da je za uporabu kod liječenja.
19. Spoj prema formuli (I) ili njegova farmaceutski prihvatljiva sol prema bilo kojem od zahtjeva 1 do 14 naznačen time da je za uporabu kod liječenja bolesti ili stanja opstruktivnih dišnih puteva.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US91658607P | 2007-05-08 | 2007-05-08 | |
US2495708P | 2008-01-31 | 2008-01-31 | |
PCT/GB2008/050328 WO2008135791A1 (en) | 2007-05-08 | 2008-05-06 | Imidazoquinolines with immuno-modulating properties |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20120895T1 true HRP20120895T1 (hr) | 2012-11-30 |
Family
ID=39596464
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20120895AT HRP20120895T1 (hr) | 2007-05-08 | 2012-11-07 | Imidazokinolini sa imuno-modulacijskim svojstvima |
Country Status (28)
Country | Link |
---|---|
US (2) | US8436178B2 (hr) |
EP (1) | EP2155743B1 (hr) |
JP (1) | JP5400763B2 (hr) |
KR (1) | KR20100016289A (hr) |
CN (1) | CN101687867B (hr) |
AR (1) | AR066492A1 (hr) |
AU (1) | AU2008247165B2 (hr) |
BR (1) | BRPI0811125A2 (hr) |
CA (1) | CA2686163A1 (hr) |
CL (1) | CL2008001357A1 (hr) |
CO (1) | CO6251247A2 (hr) |
CY (1) | CY1113339T1 (hr) |
DK (1) | DK2155743T3 (hr) |
EC (1) | ECSP099750A (hr) |
ES (1) | ES2393037T3 (hr) |
HK (1) | HK1138849A1 (hr) |
HR (1) | HRP20120895T1 (hr) |
IL (1) | IL201572A0 (hr) |
MX (1) | MX2009011802A (hr) |
MY (1) | MY150519A (hr) |
PE (1) | PE20090276A1 (hr) |
PL (1) | PL2155743T3 (hr) |
PT (1) | PT2155743E (hr) |
RU (1) | RU2475487C2 (hr) |
TW (1) | TW200902529A (hr) |
UY (1) | UY31069A1 (hr) |
WO (1) | WO2008135791A1 (hr) |
ZA (1) | ZA200907547B (hr) |
Families Citing this family (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1728793B1 (en) | 2004-03-26 | 2016-02-03 | Sumitomo Dainippon Pharma Co., Ltd. | 9-substituted 8-oxoadenine compound |
US8138172B2 (en) * | 2006-07-05 | 2012-03-20 | Astrazeneca Ab | 8-oxoadenine derivatives acting as modulators of TLR7 |
TW200831105A (en) | 2006-12-14 | 2008-08-01 | Astrazeneca Ab | Novel compounds |
ES2373616T3 (es) | 2007-03-19 | 2012-02-07 | Astrazeneca Ab | Compuestos de 8-oxo-adenina 9 sustituidos como moduladores del receptor de tipo toll (tlr7). |
ES2457316T3 (es) | 2007-03-19 | 2014-04-25 | Astrazeneca Ab | Compuestos 8-oxo-adenina 9 sustituidos como moduladores del receptor similares a toll (TLR7) |
US8044056B2 (en) * | 2007-03-20 | 2011-10-25 | Dainippon Sumitomo Pharma Co., Ltd. | Adenine compound |
AR065784A1 (es) * | 2007-03-20 | 2009-07-01 | Dainippon Sumitomo Pharma Co | Derivados de 8-oxo adenina,medicamentos que los contienen y usos como agentes terapeuticos para enfermedades alergicas, antivirales o antibacterianas. |
JP5400763B2 (ja) * | 2007-05-08 | 2014-01-29 | アストラゼネカ・アクチエボラーグ | 免疫調節特性を有するイミダゾキノリン類 |
EA024359B1 (ru) * | 2007-06-29 | 2016-09-30 | Джилид Сайэнс, Инк. | Пуриновые производные и их применение в качестве модуляторов толл-подобного рецептора 7 |
PE20091236A1 (es) | 2007-11-22 | 2009-09-16 | Astrazeneca Ab | Derivados de pirimidina como immunomoduladores de tlr7 |
PE20091156A1 (es) | 2007-12-17 | 2009-09-03 | Astrazeneca Ab | Sales de (3-{[[3-(6-amino-2-butoxi-8-oxo-7,8-dihidro-9h-purin-9-il)propil](3-morfolin-4-ilpropil)amino]metil}fenil)acetato de metilo |
US20110054168A1 (en) * | 2008-01-17 | 2011-03-03 | Ayumu Kurimoto | Method for preparing adenine compound |
KR20100125245A (ko) | 2008-01-17 | 2010-11-30 | 다이닛본 스미토모 세이야꾸 가부시끼가이샤 | 아데닌 화합물의 제조 방법 |
US8466167B2 (en) * | 2008-03-03 | 2013-06-18 | Irm Llc | Compounds and compositions as TLR activity modulators |
PL2276486T3 (pl) * | 2008-03-24 | 2014-04-30 | 4Sc Discovery Gmbh | Nowe podstawione imidazochinoliny |
AU2009333559B2 (en) | 2008-12-09 | 2015-03-12 | Gilead Sciences, Inc. | Modulators of toll-like receptors |
GB0908772D0 (en) | 2009-05-21 | 2009-07-01 | Astrazeneca Ab | New salts 756 |
AU2010290896B2 (en) | 2009-09-02 | 2014-07-03 | Glaxosmithkline Biologicals S.A. | Immunogenic compositions including TLR activity modulators |
NZ598384A (en) * | 2009-09-14 | 2014-04-30 | Gilead Sciences Inc | Modulators of toll-like receptors |
EP2491035B1 (en) | 2009-10-22 | 2017-08-30 | Gilead Sciences, Inc. | Derivatives of purine or deazapurine useful for the treatment of (inter alia) viral infections |
JP2013512859A (ja) * | 2009-12-03 | 2013-04-18 | 大日本住友製薬株式会社 | トール様受容体(tlr)を介して作用するイミダゾキノリン |
WO2011084725A1 (en) * | 2009-12-21 | 2011-07-14 | 3M Innovative Properties Company | 4-AMINO-2-(ETHOXYMETHYL)-1-(2-HYDROXY-2-METHYLPROPYL)-1H-IMIDAZO[4,5-c]QUINOLIN-5-IUM 1-HYDROXYNAPHTHALENE-2-CARBOXYLATE COMPOSITIONS AND METHODS |
US20110150836A1 (en) * | 2009-12-22 | 2011-06-23 | Gilead Sciences, Inc. | Methods of treating hbv and hcv infection |
CN103313725B (zh) | 2010-09-01 | 2016-06-29 | 诺华有限公司 | 免疫增强剂吸附不溶性金属离子 |
CN103370317B (zh) * | 2010-12-16 | 2015-10-07 | 阿斯利康(瑞典)有限公司 | 可用于治疗的咪唑并[4,5-c]喹啉-1-基衍生物 |
WO2012080730A1 (en) | 2010-12-17 | 2012-06-21 | Astrazeneca Ab | Purine derivatives |
EP2680885B8 (en) | 2011-03-02 | 2018-07-25 | GlaxoSmithKline Biologicals SA | Combination vaccines with lower doses of antigen and/or adjuvant |
MX2014002363A (es) | 2011-09-01 | 2014-04-14 | Novartis Ag | Formulaciones de antigenos de staphylococcus aureus con adyuvante. |
AU2013229465A1 (en) | 2012-03-07 | 2014-09-04 | Novartis Ag | Adjuvanted formulations of rabies virus immunogens |
JP2015510872A (ja) | 2012-03-07 | 2015-04-13 | ノバルティス アーゲー | Streptococcuspneumoniae抗原の増強された製剤 |
RU2014140521A (ru) | 2012-03-08 | 2016-04-27 | Новартис Аг | Адъювантные составы бустерных вакцин |
MY178053A (en) | 2012-05-18 | 2020-09-30 | Sumitomo Dainippon Pharma Co Ltd | Carboxylic acid compounds |
RU2015106930A (ru) | 2012-09-06 | 2016-10-20 | Новартис Аг | Комбинированные вакцины с менингококком серогруппы в и к/д/с |
AU2015205753A1 (en) | 2014-01-10 | 2016-07-21 | Birdie Biopharmaceuticals Inc. | Compounds and compositions for treating HER2 positive tumors |
CA2954446A1 (en) | 2014-07-09 | 2016-01-14 | Shanghai Birdie Biotech, Inc. | Anti-pd-l1 combinations for treating tumors |
TWI733652B (zh) | 2014-07-11 | 2021-07-21 | 美商基利科學股份有限公司 | 用於治療HIV之toll樣受體調節劑 |
EP3194401B1 (en) | 2014-09-16 | 2020-10-21 | Gilead Sciences, Inc. | Solid forms of a toll-like receptor modulator |
CN115252792A (zh) | 2016-01-07 | 2022-11-01 | 博笛生物科技有限公司 | 用于治疗肿瘤的抗-egfr组合 |
CN106943596A (zh) | 2016-01-07 | 2017-07-14 | 博笛生物科技(北京)有限公司 | 用于治疗肿瘤的抗-cd20组合 |
BR112019013911A2 (pt) * | 2017-01-06 | 2020-02-04 | Hoffmann La Roche | novas formas sólidas de acetato de [(1s)-1-[2s,4r,5r)-5-(5-amino-2-oxo-tiazolo[4,5-d]pirimidin-3-il)-4-hidroxi-tetrahidrofuran-2il]propil |
TWI674261B (zh) | 2017-02-17 | 2019-10-11 | 美商英能腫瘤免疫股份有限公司 | Nlrp3 調節劑 |
CA3057813A1 (en) | 2017-03-29 | 2018-10-04 | Sumitomo Dainippon Pharma Co., Ltd. | Vaccine adjuvant formulation |
CN108794467A (zh) | 2017-04-27 | 2018-11-13 | 博笛生物科技有限公司 | 2-氨基-喹啉衍生物 |
MX2019015744A (es) | 2017-06-23 | 2020-02-20 | Birdie Biopharmaceuticals Inc | Composiciones farmaceuticas. |
US12012421B2 (en) | 2017-07-07 | 2024-06-18 | Hoffmann-La Roche Inc. | Solid forms of [(1S)-1-[(2S,4R,5R)-5-(5-amino-2-oxo-thiazolo[4,5-d]pyrimidin-3-yl)-4-hydroxy-tetrahydrofuran-2-yl]propyl] acetate |
WO2019048036A1 (en) * | 2017-09-06 | 2019-03-14 | Biontech Ag | SUBSTITUTED IMIDAZOQUINOLINES |
US12012420B2 (en) | 2017-11-21 | 2024-06-18 | Hoffmann-La Roche, Inc. | Solid forms of [(1S)-1-[(2S,4R,5R)-5-(5-amino-2-oxo-thiazolo[4,5-d]pyrimidin-3-yl)-4-hydroxy-tetrahydrofuran-2-yl]propyl] acetate |
EP3728255B1 (en) | 2017-12-20 | 2022-01-26 | 3M Innovative Properties Company | Amide substituted imidazo[4,5-c]quinoline compounds with a branched chain linking group for use as an immune response modifier |
CN116115765A (zh) | 2017-12-21 | 2023-05-16 | 住友制药株式会社 | 包含tlr7激动剂的组合药物 |
JP7395461B2 (ja) | 2018-07-23 | 2023-12-11 | 国立感染症研究所長 | インフルエンザワクチンを含む組成物 |
US11339159B2 (en) | 2019-07-17 | 2022-05-24 | Pfizer Inc. | Toll-like receptor agonists |
CN114761406B (zh) * | 2019-12-03 | 2024-04-19 | 豪夫迈·罗氏有限公司 | 用于治疗自身免疫性疾病的氢吡啶并[1,2-a]吡嗪化合物 |
CN115916342A (zh) * | 2020-07-08 | 2023-04-04 | 普渡研究基金会 | 用于治疗纤维化疾病和癌症的化合物、组合物和方法 |
US20230390409A1 (en) | 2020-10-30 | 2023-12-07 | Avacta Life Sciences Limited | Fap-activated serum extended half-life therapeutic conjugates |
Family Cites Families (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE8404768L (sv) | 1983-09-27 | 1985-03-28 | Ceskoslovenska Akademie Ved | 9-(aminoalkyl)-8-hydroxiadeniner och sett for deras framstellning |
ZA848968B (en) * | 1983-11-18 | 1986-06-25 | Riker Laboratories Inc | 1h-imidazo(4,5-c)quinolines and 1h-imidazo(4,5-c)quinolin-4-amines |
IL73534A (en) * | 1983-11-18 | 1990-12-23 | Riker Laboratories Inc | 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds |
IL78643A0 (en) * | 1985-05-02 | 1986-08-31 | Wellcome Found | Purine derivatives,their preparation and pharmaceutical compositions containing them |
GB8918267D0 (en) * | 1989-08-10 | 1990-04-25 | British Aerospace | Weapon systems |
SG70625A1 (en) * | 1991-03-01 | 2000-02-22 | Minnesota Mining & Mfg | 1-Substituted 2-substituted 1H-imidazo(4, 5-c) quinolin-4-amines |
JPH08165292A (ja) | 1993-10-07 | 1996-06-25 | Techno Res Kk | アデニン誘導体、その製造法及び用途 |
US6110923A (en) | 1994-06-22 | 2000-08-29 | Biochem Pharma Inc. | Method for treating cancer using novel substituted purinyl derivatives with immunomodulating activity |
HUT77436A (hu) | 1994-10-05 | 1998-04-28 | Darwin Discovery Limited | Purin- és guaninszármazékok, eljárás előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk gyógyszerkészítmények előállítására |
NZ329798A (en) | 1996-07-03 | 1999-04-29 | Japan Energy Corp | Purine derivatives their tautomers and salts thereof and interferon secretion inducers, antiviral agents and anticancer drugs containing the same |
AU732361B2 (en) * | 1997-11-28 | 2001-04-26 | Dainippon Sumitomo Pharma Co., Ltd. | Novel heterocyclic compounds |
JPH11180981A (ja) | 1997-12-19 | 1999-07-06 | Sumitomo Pharmaceut Co Ltd | 複素環誘導体 |
TW572758B (en) * | 1997-12-22 | 2004-01-21 | Sumitomo Pharma | Type 2 helper T cell-selective immune response inhibitors comprising purine derivatives |
JP4160645B2 (ja) | 1997-12-24 | 2008-10-01 | 大日本住友製薬株式会社 | 新規アデニン誘導体及びその医薬用途 |
JP4189048B2 (ja) | 1997-12-26 | 2008-12-03 | 大日本住友製薬株式会社 | 複素環化合物 |
ATE267175T1 (de) * | 1998-08-27 | 2004-06-15 | Sumitomo Pharma | Pyrimidin derivate |
JP2000159767A (ja) | 1998-11-26 | 2000-06-13 | Sumitomo Pharmaceut Co Ltd | 8−ヒドロキシアデニン誘導体の新規製造法 |
CZ27399A3 (cs) * | 1999-01-26 | 2000-08-16 | Ústav Experimentální Botaniky Av Čr | Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv |
US6451810B1 (en) * | 1999-06-10 | 2002-09-17 | 3M Innovative Properties Company | Amide substituted imidazoquinolines |
US6573273B1 (en) * | 1999-06-10 | 2003-06-03 | 3M Innovative Properties Company | Urea substituted imidazoquinolines |
US6541485B1 (en) * | 1999-06-10 | 2003-04-01 | 3M Innovative Properties Company | Urea substituted imidazoquinolines |
US6756382B2 (en) * | 1999-06-10 | 2004-06-29 | 3M Innovative Properties Company | Amide substituted imidazoquinolines |
US6331539B1 (en) * | 1999-06-10 | 2001-12-18 | 3M Innovative Properties Company | Sulfonamide and sulfamide substituted imidazoquinolines |
GB9924361D0 (en) * | 1999-10-14 | 1999-12-15 | Pfizer Ltd | Purine derivatives |
US20020040032A1 (en) * | 2000-07-07 | 2002-04-04 | Glasky Michelle S. | Methods for stimulation of synthesis of synaptophysin in the central nervous system |
WO2002004449A2 (en) * | 2000-07-07 | 2002-01-17 | Neotherapeutics, Inc. | Methods for treatment of conditions affected by activity of multidrug transporters |
AU2001273212A1 (en) * | 2000-07-07 | 2002-01-21 | Neotherapeutics, Inc. | Methods for treatment of drug-induced peripheral neuropathy and related conditions |
AU2002239277A1 (en) * | 2000-11-20 | 2002-05-27 | Cor Therapeutics, Inc. | Adenine based inhibitors of adenylyl cyclase, pharmaceutical compositions and method of use thereof |
SI1341791T1 (en) | 2000-12-08 | 2005-10-31 | 3M Innovative Properties Company | Thioether substituted imidazoquinolines |
US6677348B2 (en) * | 2000-12-08 | 2004-01-13 | 3M Innovative Properties Company | Aryl ether substituted imidazoquinolines |
CN1250548C (zh) * | 2001-04-17 | 2006-04-12 | 大日本住友制药株式会社 | 新的腺嘌呤衍生物 |
ITRM20010465A1 (it) * | 2001-07-31 | 2003-01-31 | Sigma Tau Ind Farmaceuti | Derivati della triazolil-imidazopiridina e delle triazolilpurine utili come ligandi del recettore a2a dell'adenosina e loro uso come medicam |
JP2005513021A (ja) * | 2001-11-16 | 2005-05-12 | スリーエム イノベイティブ プロパティズ カンパニー | Irm化合物およびトール様受容体経路に関する方法および組成物 |
US20060252774A1 (en) * | 2002-05-02 | 2006-11-09 | Vatner Stephen F | Regulation of type 5 adenylyl cyclase for treatment of neurodegenerative and cardiac diseases |
ATE488246T1 (de) * | 2002-08-15 | 2010-12-15 | 3M Innovative Properties Co | Immunstimulatorische zusammensetzungen und verfahren zur stimulierung einer immunantwort |
BR0314761A (pt) | 2002-09-27 | 2005-07-26 | Sumitomo Pharma | Composto de adenina e seu uso |
JP2004137157A (ja) | 2002-10-16 | 2004-05-13 | Sumitomo Pharmaceut Co Ltd | 新規アデニン誘導体を有効成分として含有する医薬 |
BRPI0411514A (pt) * | 2003-06-20 | 2006-08-01 | Coley Pharm Gmbh | antagonistas de receptor toll-like de molécula pequena |
BRPI0414045A (pt) * | 2003-09-05 | 2006-10-24 | Anadys Pharmaceuticals Inc | administração de ligantes de tlr7 e pró-medicamentos dos mesmos para tratamento de infecção por vìrus de hepatite c |
JP2005089334A (ja) | 2003-09-12 | 2005-04-07 | Sumitomo Pharmaceut Co Ltd | 8−ヒドロキシアデニン化合物 |
EP1728793B1 (en) * | 2004-03-26 | 2016-02-03 | Sumitomo Dainippon Pharma Co., Ltd. | 9-substituted 8-oxoadenine compound |
WO2005092892A1 (ja) * | 2004-03-26 | 2005-10-06 | Dainippon Sumitomo Pharma Co., Ltd. | 8−オキソアデニン化合物 |
WO2006117670A1 (en) * | 2005-05-04 | 2006-11-09 | Pfizer Limited | 2-amido-6-amino-8-oxopurine derivatives as toll-like receptor modulators for the treatment of cancer and viral infections, such as hepatitis c |
WO2006129784A1 (ja) | 2005-06-03 | 2006-12-07 | Riken | インターフェロン-α制御剤 |
ES2577514T3 (es) * | 2005-08-22 | 2016-07-15 | The Regents Of The University Of California | Antagonistas de TLR |
TW200801003A (en) * | 2005-09-16 | 2008-01-01 | Astrazeneca Ab | Novel compounds |
EP1939198A4 (en) * | 2005-09-22 | 2012-02-15 | Dainippon Sumitomo Pharma Co | NEW ADENINE CONNECTION |
US20090118263A1 (en) * | 2005-09-22 | 2009-05-07 | Dainippon Sumitomo Pharma Co., Ltd. | Novel Adenine Compound |
JPWO2007034917A1 (ja) * | 2005-09-22 | 2009-03-26 | 大日本住友製薬株式会社 | 新規なアデニン化合物 |
TW200745114A (en) * | 2005-09-22 | 2007-12-16 | Astrazeneca Ab | Novel compounds |
EP1939200A4 (en) * | 2005-09-22 | 2010-06-16 | Dainippon Sumitomo Pharma Co | NEW ADENINE CONNECTION |
JPWO2007034882A1 (ja) * | 2005-09-22 | 2009-03-26 | 大日本住友製薬株式会社 | 新規アデニン化合物 |
US20090281075A1 (en) * | 2006-02-17 | 2009-11-12 | Pharmacopeia, Inc. | Isomeric purinones and 1h-imidazopyridinones as pkc-theta inhibitors |
US8138172B2 (en) * | 2006-07-05 | 2012-03-20 | Astrazeneca Ab | 8-oxoadenine derivatives acting as modulators of TLR7 |
US8338593B2 (en) * | 2006-07-07 | 2012-12-25 | Gilead Sciences, Inc. | Modulators of toll-like receptor 7 |
TW200831105A (en) * | 2006-12-14 | 2008-08-01 | Astrazeneca Ab | Novel compounds |
WO2008101867A1 (en) * | 2007-02-19 | 2008-08-28 | Smithkline Beecham Corporation | Purine derivatives as immunomodulators |
ES2457316T3 (es) * | 2007-03-19 | 2014-04-25 | Astrazeneca Ab | Compuestos 8-oxo-adenina 9 sustituidos como moduladores del receptor similares a toll (TLR7) |
ES2373616T3 (es) * | 2007-03-19 | 2012-02-07 | Astrazeneca Ab | Compuestos de 8-oxo-adenina 9 sustituidos como moduladores del receptor de tipo toll (tlr7). |
AR065784A1 (es) * | 2007-03-20 | 2009-07-01 | Dainippon Sumitomo Pharma Co | Derivados de 8-oxo adenina,medicamentos que los contienen y usos como agentes terapeuticos para enfermedades alergicas, antivirales o antibacterianas. |
US8044056B2 (en) * | 2007-03-20 | 2011-10-25 | Dainippon Sumitomo Pharma Co., Ltd. | Adenine compound |
JP5400763B2 (ja) * | 2007-05-08 | 2014-01-29 | アストラゼネカ・アクチエボラーグ | 免疫調節特性を有するイミダゾキノリン類 |
EA024359B1 (ru) * | 2007-06-29 | 2016-09-30 | Джилид Сайэнс, Инк. | Пуриновые производные и их применение в качестве модуляторов толл-подобного рецептора 7 |
PE20091236A1 (es) * | 2007-11-22 | 2009-09-16 | Astrazeneca Ab | Derivados de pirimidina como immunomoduladores de tlr7 |
US20110054168A1 (en) * | 2008-01-17 | 2011-03-03 | Ayumu Kurimoto | Method for preparing adenine compound |
KR20100125245A (ko) * | 2008-01-17 | 2010-11-30 | 다이닛본 스미토모 세이야꾸 가부시끼가이샤 | 아데닌 화합물의 제조 방법 |
CN101239980B (zh) | 2008-02-18 | 2011-06-22 | 靳广毅 | 免疫受体调节剂偶联体前体和偶联体及其应用 |
WO2009151910A2 (en) * | 2008-05-25 | 2009-12-17 | Wyeth | Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer |
UA103195C2 (uk) * | 2008-08-11 | 2013-09-25 | Глаксосмитклайн Ллк | Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань |
GB0908772D0 (en) * | 2009-05-21 | 2009-07-01 | Astrazeneca Ab | New salts 756 |
JP2013512859A (ja) * | 2009-12-03 | 2013-04-18 | 大日本住友製薬株式会社 | トール様受容体(tlr)を介して作用するイミダゾキノリン |
-
2008
- 2008-05-06 JP JP2010507003A patent/JP5400763B2/ja not_active Expired - Fee Related
- 2008-05-06 KR KR1020097023214A patent/KR20100016289A/ko not_active Application Discontinuation
- 2008-05-06 EP EP08737252A patent/EP2155743B1/en active Active
- 2008-05-06 CA CA002686163A patent/CA2686163A1/en not_active Abandoned
- 2008-05-06 AU AU2008247165A patent/AU2008247165B2/en not_active Ceased
- 2008-05-06 MX MX2009011802A patent/MX2009011802A/es active IP Right Grant
- 2008-05-06 WO PCT/GB2008/050328 patent/WO2008135791A1/en active Application Filing
- 2008-05-06 BR BRPI0811125A patent/BRPI0811125A2/pt not_active IP Right Cessation
- 2008-05-06 ES ES08737252T patent/ES2393037T3/es active Active
- 2008-05-06 DK DK08737252.0T patent/DK2155743T3/da active
- 2008-05-06 CN CN2008800240506A patent/CN101687867B/zh not_active Expired - Fee Related
- 2008-05-06 RU RU2009140465/04A patent/RU2475487C2/ru not_active IP Right Cessation
- 2008-05-06 MY MYPI20094714 patent/MY150519A/en unknown
- 2008-05-06 US US12/596,817 patent/US8436178B2/en not_active Expired - Fee Related
- 2008-05-06 PL PL08737252T patent/PL2155743T3/pl unknown
- 2008-05-06 PT PT08737252T patent/PT2155743E/pt unknown
- 2008-05-07 TW TW097116797A patent/TW200902529A/zh unknown
- 2008-05-07 UY UY31069A patent/UY31069A1/es not_active Application Discontinuation
- 2008-05-08 PE PE2008000806A patent/PE20090276A1/es not_active Application Discontinuation
- 2008-05-08 AR ARP080101952A patent/AR066492A1/es not_active Application Discontinuation
- 2008-05-08 CL CL2008001357A patent/CL2008001357A1/es unknown
-
2009
- 2009-10-15 IL IL201572A patent/IL201572A0/en unknown
- 2009-10-22 CO CO09118667A patent/CO6251247A2/es not_active Application Discontinuation
- 2009-10-27 ZA ZA2009/07547A patent/ZA200907547B/en unknown
- 2009-11-20 EC EC2009009750A patent/ECSP099750A/es unknown
-
2010
- 2010-06-10 HK HK10105771.2A patent/HK1138849A1/xx not_active IP Right Cessation
-
2012
- 2012-11-07 HR HRP20120895AT patent/HRP20120895T1/hr unknown
- 2012-11-14 CY CY20121101089T patent/CY1113339T1/el unknown
-
2013
- 2013-03-14 US US13/830,042 patent/US20130225555A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20120895T1 (hr) | Imidazokinolini sa imuno-modulacijskim svojstvima | |
HRP20130174T1 (hr) | Derivati pirimidina za lijeäśenje astme, kopb, alergijskog rinitisa, alergijskog konjuktivitisa, atopijskog dermatitisa, karcinoma, hepatitisa b, hepatitisa c, hiv, hpv, bakterijskih infekcija i dermatoze | |
JP2010526129A5 (hr) | ||
ES2629414T3 (es) | Derivados de tiazol | |
BRPI0920966A2 (pt) | derivado de piridina-3-carboxiamida | |
NO20063681L (no) | Aryloksyalkylkarbamattype derivater, fremgangsmate for fremstilling derav og anvendelse av derivatene i terapeutiske midler | |
ES2520647T3 (es) | Compuestos de triazolopiridina | |
HRP20140503T1 (hr) | Derivati tieno-piridina kao inhibitori mek | |
CA2371583A1 (en) | Piperazine derivatives useful as ccr5 antagonists | |
MEP22008A (en) | Derivatives of n-[heteroaryl(piperidine-2-yl)methyl]benzamide, preparation method thereof and application of same in therapeutics | |
HRP20070430T3 (hr) | (3-okso-3,4-dihidro-kiinoksalin-2-il-amino)-benzamidni derivati i srodni spojevi kao inhibitori glikogen-fosforilaze za liječenje dijabetesa i pretilosti | |
CA2371587A1 (en) | Piperidine derivatives useful as ccr5 antagonists | |
TNSN05252A1 (en) | Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders : process for their preparation and pharmaceutical compositions containing them | |
PE20090183A1 (es) | Derivados de 1-oxa-3,9-diaza-espiro-[5.5]undecan-2-ona como moduladores de ccr5 | |
NO20092286L (no) | Nitrogenhaldige heterosykliske forbindelser og anvendelse derav | |
NO20073926L (no) | Pyrazolforbindelser som modulerer aktivitet av CDK-, GSK- og aurorakinaser | |
NO20075059L (no) | Nye forbindelser II 2-pyridinderivater som inhibitorer av neutrofil elastase | |
RS20060201A (en) | 1,1,1,-trifluoro-4-phenyl-4-methyl-2-(1h-pyrrolo | |
TW200633979A (en) | Method | |
NO20072371L (no) | Kinuklidinderivater og deres anvendelse som muskarine M3-reseptorantagonister | |
NO20070173L (no) | Nye forbindelser | |
ATE476431T1 (de) | Piperidin- und azetidinderivate als glyt1- inhibitoren | |
JP2007521287A5 (hr) | ||
JP6602856B2 (ja) | キナーゼ阻害剤としてのピラゾロ−ピリジン誘導体 | |
JP2017521480A (ja) | ベンゼンスルホンアミド誘導体及びrorcモデュレーターとしてのその使用 |